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ABSTRACT OF DISSERTATION
Pharmacokinetic and Pharmacodynamic Evaluation of Cocaine Hydrolases for the
Treatment of Cocaine Overdose and Cocaine Addiction Using Rodent Models
Overdose and addiction are two medical complications of cocaine abuse. To date,
there is no FDA approved pharmacotherapy specific for cocaine abuse. Cocaine hydrolases
(CocHs) have been extensively investigated for its potential in anti-cocaine therapy.
Previous studies have demonstrated that CocHs efficiently hydrolyze cocaine to generate
biologically inactive metabolites both in vivo and in vitro. However, it has not been studied
whether there is gender difference in the therapy using CocHs. In addition, the
effectiveness of CocHs is unknown for treating cocaine toxicity when alcohol is coadministered.
The main purpose of this dissertation is to characterize and evaluate efficient CocHs
for cocaine overdose and cocaine addiction treatment. In the first set of studies, the
effectiveness of human serum albumin-fused CocH1 were studied in male and female rats.
The pharmacokinetic profiles, as well as the pharmacodynamic effects of CocH1-HSA
were compared in male and female rats. The obtained data clearly demonstrated that
CocH1-HSA was equally effective in both genders. The second set of studies investigated
the efficiency of Fc-fused CocH5 in reversing cocaine toxicity in rats receiving
simultaneous administration of cocaine and alcohol. Results showed that CocH5-Fc rapidly
hydrolyzed cocaine and cocaine’s toxic metabolites in rats, and demonstrated that CocH5Fc was efficient in treating cocaine toxicity when alcohol was simultaneously administered.
In later studies to investigate the effects of CocH5-Fc for the treatment of cocaine
addiction, a mathematical model was developed and validated to predict the effects of
CocH5-Fc on the disposition of cocaine in rat blood and brain. This model adequately
described the effects of CocH5-Fc in accelerating the elimination of cocaine and its toxic
metabolites in both rat blood and brain. In conclusion, the studies within the current
dissertation demonstrate the clinical potential of CocHs for the treatment of both cocaine
overdose and cocaine addiction.

KEYWORDS: Cocaine overdose, cocaine addiction, cocaine hydrolase, mathematical
model.
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CHAPTER 1. INTRODUCTION

1.1

Introduction to cocaine
Cocaine is a highly addictive drug that continues to be a world-wide health concern

(Connors et al. 2013). An estimated 18 million people around the world consumed cocaine
in 2016 (World Drug Report 2018), and more than 10,000 cocaine-related deaths were
reported in the United States in the same year (Seth et al. 2018).
Overdose and addiction are two medical complications of cocaine abuse (Becker
1979). Small amount of cocaine use results in euphoria, increased energy, reduced fatigue,
elevated blood pressure and heart rate (Ciccarone 2011). When a person consumes a large
amount of cocaine, overdose/acute toxicity may occur, resulting in neurological effects
such as hyperexcitation, stroke, seizures, and cardiovascular effects such as hypertension
and myocardial infarction (Heard et al. 2008). In rare instances, sudden death results from
cardiac arrest or seizures can occur unexpectedly (Benowitz 1993).
Cocaine addiction is a chronic brain disease characterized by loss of control over
drug use, or compulsive drug seeking and drug taking despite adverse consequences
(Nestler 2001, Everitt et al. 2005). Addicted patients show withdrawal symptoms, craving
for drug use, and increased risk for relapse even after a long period of abstinence (Everitt
et al. 2005). Cocaine use also can lead to public problems such as infectious disease,
increased violence and crime (Karila et al. 2008).
In addition, more than 70% of cocaine users concurrently consume alcohol during
their binges (Snenghi et al. 2018). Increased heart rate, cerebral infarction, intracranial
hemorrhage, myocardial infarction, and cardiac arrhythmias have been reported in patients
1

that simultaneously consume alcohol and cocaine (McCance-Katz et al. 1998, Farooq et
al. 2009).
1.2

Mechanism of cocaine toxicity
The mechanism of cocaine toxicity is complex and involves simultaneous

stimulation on multiple targets. Cocaine targets multiple proteins, including dopamine
transporter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET),
with Ki values of 0.64, 0.14, and 1.6 M, respectively (Heard et al. 2008). By blocking
these transporters, cocaine prevents the re-uptake of these neurotransmitters, leading to
elevated neurotransmitter levels in synapse, and continuous stimulation of post-synaptic
receptors (Heard et al. 2008).
Blockage of DAT is believed to be the primary mechanism that cocaine produces
stimulant effects (Ritz et al. 1987). Dopamine (DA) plays an important role in the
rewarding pathways, and DAT is responsible for the re-uptake of DA from synaptic cleft
and terminates the synaptic transmission of DA (Kalivas 2007). Cocaine inhibits the
dopamine binding to DAT, resulting in elevated extracellular dopamine level in the synapse
and increased activation of post-synaptic dopamine receptors, thus leading to stimulant
effects (Volkow et al. 1997). Once experienced, cocaine-induced reinforcing effects
promote the repeated use of cocaine. Over time, chronic exposure to cocaine disrupts the
reward circuits and produces neuroadaptations (Dackis et al. 2005). For example,
decreased dopamine D2 receptors were observed in monkeys self-administered cocaine for
18 months (Moore et al. 1998). Ultimately, neuroadaptations may lead to the transition to
drug addiction (Ferrario et al. 2005), and cocaine becomes difficult to resist (Piazza et al.
2013).
2

In addition to DAT, according to recent reported studies, SERT blockade also
contributes to the rewarding effects of cocaine (Sora et al. 2001). It has been found that
DAT-knock out (KO) mice still experience the rewarding effects of cocaine by modulating
the serotonin system (Mateo et al. 2004). In comparison, no cocaine-induced preference
for places was observed in the double DAT-KO/SERT-KO mice (Sora et al. 2001). In
addition, SERT also contributes to cocaine-induced acute toxicity. It has been reported that
pre-treatment of SERT inhibitor dose-dependently decreased the latency of cocaineinduced convulsion and increased the occurrence of seizures in mice (Macêdo et al. 2004).
In the peripheral nervous system, cocaine blocks NET and results in accumulated
norepinephrine (NE) in the synaptic cleft. NE stimulates both the - and -adrenergic
receptors in the heart and blood vessels, which produces constriction of blood vessels and
increased heart rate. These effects may lead to hypertension and tachycardia (Brick 2012).
Cocaine also binds to ion channels, such as sodium channels and calcium channels
in cardiac myocytes, which may also contribute to cocaine-induced cardiotoxicity (Heard
et al. 2008). For example, the inhibition of inward flux of sodium induced by cocaine,
together with the increased adrenergic activity, may result in conduction delays and
dysrhythmias (Maraj et al. 2010, Brick 2012).
1.3

Current pharmacodynamic approaches for cocaine treatment
Despite the therapeutic demand, there is no Food and Drug Administration (FDA)

approved pharmacotherapy specific for anti-cocaine treatment (Chan et al. 2018). Current
pharmacological approaches for anti-cocaine treatment use small-molecule drugs to
modulate or disrupt the pharmacodynamic effects of cocaine at the sites of action (Gorelick
2012). These include two approaches: 1) developing selective ligands that directly act on
3

dopamine system; 2) modulation of other neurotransmitter systems that indirectly affect
dopaminergic rewarding system (Gorelick et al. 2004).
Drugs directly acting on dopamine system include compounds that block dopamine
transporter, and compounds that antagonize dopamine receptor (Raje et al. 2003, Gorelick
et al. 2004). For example, a DAT inhibitor, N-(2-((bis(4-fluorophenyl)methyl)thio)ethyl)3-phenylpropan-1-amine (also known as JJC8-016), was evaluated in rats. JJC8-016 was
reported to significantly and dose-dependently inhibit intravenous cocaine selfadministration, cocaine-enhanced locomotion, and cocaine-induced reinstatement of drugseeking behavior in rats (Zhang et al. 2017).
An alternative approach includes manipulating other neurotransmitter systems,
such as -aminobutyric acid (GABA) system, N-methyl D-aspartate (NMDA)-glutamate
system, and serotonin system (Heard et al. 2008). For example, ()-baclofen, a GABAB
receptor agonist has shown anti-cocaine potentials in animal studies. ()-Baclofen has been
reported to dose-dependently inhibit cocaine-induced acute seizures in mice (Gasior et al.
2004), and dose-dependently attenuate cocaine-seeking behavior in rats (Di Ciano et al.
2003).
However, despite the success in animal studies, it is challenging for a smallmolecule drug to block cocaine-induced effects without affecting the normal function of
central nervous system (CNS) (Zheng et al. 2012). For example, toxic effects, including
seizure, were observed in patients receiving effective dose of baclofen (Kiel et al. 2015).
Additionally, as cocaine acts on neurotransmitter transporters and ion channels
simultaneously, it is difficult for these medications to fully block cocaine’s effects by
focusing on only one of these targets (Schindler et al. 2012). Further, norcocaine and

4

benzoylecgonine, which are toxic metabolites of cocaine, may be present at high
concentrations when a patient visits an emergency department (Connors et al. 2013). The
efficacy of above mentioned medications on reducing toxicity induced by these toxic
metabolites remains unknown (Connors et al. 2013). Taken together, the small-molecule
drug approach has not yet proven to be therapeutically valuable in anti-cocaine treatment.
1.4

Current pharmacokinetic approaches for cocaine treatment
An

alternative

approach

for

cocaine

treatment

involves

altering

the

pharmacokinetic profiles of cocaine and keeping cocaine concentration below the minimal
effective concentration (Zheng et al. 2012). This approach has been explored in both preclinical and clinical studies using anti-cocaine antibodies and cocaine-metabolizing
enzymes (Gorelick et al. 2004). Antibodies prevent cocaine from entering the brain by
forming a complex that is too large to cross the blood brain barrier, thus reducing cocaine
concentrations at its site of action (Gorelick et al. 2004). However, antibodies
stoichiometrically bind with cocaine and can be saturated by cocaine molecules, making
the patients easily overcome the therapeutic effects by simply increasing drug-intake. In
comparison, enzymes not only bind with, but also degrade cocaine molecules, depending
on the turnover number (kcat) and Michaelis-Menten constant (KM). Therefore, a cocainemetabolizing enzyme is expected to be more promising for anti-cocaine treatment (Zheng
et al. 2012).
1.5

Pharmacokinetics of cocaine in humans
Cocaine is rapidly and extensively metabolized via three pathways in humans, as

shown in Figure 1.1 : 1) hydrolysis to generate ecgonine methyl ester (EME) by
5

butyrylcholinesterase (BChE); 2) hydrolysis to generate benzoylecgonine (BE), either
spontaneously or by carboxylesterase; 3) de-methylation to generate norcocaine (NC) by
liver microsomal cytochrome P450 (Gorelick 1997). Only less than 5% of cocaine is
excreted unchanged in the urine (Benowitz 1993).
Among these metabolites, NC can be further metabolized to generate Nhydroxynorcocaine and norcocaine nitroxide, which covalently bind to cellular proteins
and cause cellular damage (Goldstein et al. 2009). It has been reported that rats receiving
equimolar infusion of norcocaine developed earlier onset of convulsion and respiratory
arrest than those receiving cocaine (Mets et al. 1995). In addition, another metabolite BE,
was reported to have more vasoconstrictive effects than cocaine itself, by a mechanism
involving blockage of calcium channels (Madden et al. 1995). Having a longer elimination
half-life than cocaine in humans (Madden et al. 1990), BE produces constrictive effects
that may thus explain some of the long-term toxic effects after cocaine use, such as reduced
cerebral blood flow and headache (Madden et al. 1990). In comparison, EME has a slightly
vasodilatory effect (Madden et al. 1990). Therefore, an increasing effort has been focused
on exploring the clinical potential of BChE, the enzyme that catalyzes the hydrolysis of
cocaine to generate EME.

6

Figure 1.1 Schematic representation of cocaine metabolic pathway.

7

1.6

Introduction to BChE
Butyrylcholinesterase (BChE) was known as pseudocholinesterase without critical

physiological function (Chatonnet et al. 1989), suggesting its safety as a therapeutic
candidate. In rats i.v. administered with BChE that exceeds plasma level hundreds-fold, no
adverse effect on the cardiovascular, autonomic, or central nervous systems was observed
(Lynch et al. 1997). 32 mg/kg i.v. administered human BChE produced no clinical sign of
toxicity in rhesus monkeys (Saxena et al. 2006). However, despite the theoretical potential
of BChE for anti-cocaine treatment, the major limitation of wild-type BChE is its low
catalytic activity against naturally occurring cocaine, with kcat = 4.1 min-1 and KM = 4.5
M (Sun et al. 2002).
1.7

Rationally designed cocaine hydrolases
Two key factors have been suggested for successful enzyme approach in anti-

cocaine treatment: 1) the therapy should efficiently reduce cocaine concentration after
cocaine intake, to prevent acute cocaine toxicity or overdose; 2) the therapy should have
long-term effects in reducing cocaine concentration in the brain, to prevent drug-addicted
patient from experiencing any reinforcing effect and thus reducing the chance of relapse
(Gorelick 2012). These factors lead to two considerations in designing an effective cocainemetabolizing enzyme: improving catalytic activity and prolonging in vivo half-life.
Through rational design, a series of BChE mutants have been developed with
significantly improved catalytic activity against (-)-cocaine. These BChE mutants were
recognized as “true cocaine hydrolases (CocHs)” (Brimijoin et al. 2008). For example,
CocH1 (the A199S/S287G/A328W/Y332G mutant of BChE), the first generation of
8

CocHs, has ~1000 fold increased catalytic efficiency against (-)-cocaine, compared to wildtype BChE (Pan et al. 2005). CocH3 (the A199S/F227A/S287G/A328W/Y332G mutant of
BChE) has further improved activity against (-)-cocaine, compared to CocH1 (Zheng et al.
2008, Xue et al. 2013). Both CocH1 and CocH3 were proved to be efficient in hydrolyzing
cocaine and its metabolites benzoylecgonine, norcocaine, and cocaethylene, a
transesterification product of cocaine reacting with ethanol (Hou et al. 2014, Zhan et al.
2014, Chen et al. 2016). Further, by using a two-step computational design approach,
CocH5 (the A199S/F227A/P285A/S287G/A328W/Y332G mutant of BChE) was designed,
and it is the most efficient cocaine-hydrolyzing enzyme reported so far (Zheng et al. 2014).
An ideal cocaine-metabolizing enzyme for the treatment of cocaine addiction is
also expected to have a long biological half-life in the long-term treatment. Recently, our
lab reported a long-acting CocH form, i.e. CocH3-Fc(3M), in which a triple-mutated
(A1V/D142E/L144M) Fc region of human immunoglobulin G1 (IgG1) was fused to the Cterminus of CocH3. CocH3-Fc(3M) had a half-life of ~107 h in rats and accelerated cocaine
metabolism in rats for at least 20 days (Chen et al. 2016).
1.8

Clinical potential of CocHs
The safety and efficacy of CocHs has been investigated in clinical studies. An

albumin-fused CocH1, also known as TV-1380, was examined in clinical trials by Teva
Pharmaceutical Industries as a treatment for cocaine addiction. The clinical results have
demonstrated that TV-1380 was safe for cocaine addiction treatment. The activities of
endogenous BChE and acetylcholinesterase (AChE) were not changed in TV-1380 treated
subjects, and no serious side effect was observed in patients treated with TV-1380 (CohenBarak et al. 2015, Gilgun-Sherki et al. 2016). Although the therapeutic effects of TV-1380
9

were limited due to the short elimination half-life, a non-significant increase in abstinence
rates in patients encouraged future improvement of CocHs (Cohen-Barak et al. 2015,
Gilgun-Sherki et al. 2016).
1.9

Objectives and Specific Aims
The overall objective of this dissertation is to identify and characterize the most

promising CocH candidate for future pre-clinical and clinical development of cocaine
overdose and cocaine addiction treatment. The identified enzyme is expected to have not
only high catalytic activities against cocaine and its toxic metabolites, but also a long
biological half-life. Three projects are involved in this dissertation and the specific aims of
each project are described as follows:
Specific Aim 1: Evaluate the effectiveness of human serum albumin (HSA)-fused
cocaine hydrolase (CocH1-HSA) in treating cocaine overdose in both genders. This work
is discussed in Chapter 2.
Aim 1.1: Compare the pharmacokinetic profiles of CocH1-HSA in male and female
rats.
Aim 1.2: Demonstrate the effectiveness of CocH1-HSA in treating cocaine toxicity
in both genders.
The findings from Specific Aim 1 demonstrated that CocH1-HSA was equally
effective in reducing cocaine toxicity in both genders. Next we wanted to investigate the
effectiveness of cocaine hydrolase in eliminating cocaine toxicity when cocaine is coadministered with alcohol. The rationale for this was based on the observation that alcohol
potentiates cocaine toxicity. Our hypothesis is that cocaine hydrolase is effective in
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reducing toxicity results from combined use of cocaine and alcohol. The studies we
conducted are discussed in Specific Aim 2.
Specific Aim 2: Investigate the clinical potential of an efficient cocaine hydrolase
to treat toxicity resulted from simultaneous use of alcohol and cocaine. This work is
discussed in Chapter 3.
Aim 2.1: Investigate the effect of alcohol on the metabolic profiles of cocaine.
Aim 2.2: Compare the lethality of cocaine and its toxic metabolites in mice.
Aim 2.3: Demonstrate the therapeutic potential of CocH5-Fc(6M) in reducing
cocaine toxicity in rats, when alcohol was co-administered.
The findings from Specific Aim 1 and 2 demonstrated the clinical potential of the
cocaine hydrolase in treating cocaine overdose. Next we wanted to switch the focus to
cocaine addiction treatment. Our hypothesis was that a long-acting cocaine hydrolase is
efficient in reducing cocaine concentration in the brain, which is the site of action for
cocaine to exert its rewarding effects. We also aimed to develop a mathematical model to
predict cocaine and its metabolites levels in rat blood and brain. This model is expected to
facilitate further in vivo studies. The studies we conducted are outlined in Specific Aim 3.
Specific Aim 3: Investigate the capacity of cocaine hydrolase in treating cocaine
addiction. This work is discussed in Chapter 4.
Aim 3.1: Investigate the pharmacokinetic profiles of CocH5-Fc(6M) in rats.
Aim 3.2: Demonstrate the effects of CocH5-Fc(6M) in eliminating cocaine and its
toxic metabolites in rat blood and brain.
Aim 3.3: Develop a mathematical model to predict the effects of cocaine hydrolase
in preventing the distribution of cocaine to rat brain.
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CHAPTER 2. EFFECTIVENESS OF A COCAINE HYDROLASE FOR COCAINE
TOXICITY TREATMENT IN MALE AND FEMALE RATS

2.1

Introduction
Cocaine overdose contributed to a high frequency of emergency department visits

(Miró et al. 2019), and led to more than 10,000 deaths in the United States in 2016 (Seth
et al. 2018). The major acute toxicity induced by cocaine include effects acting on the
central nervous system (CNS) such as agitation and seizure, and effects acting on
cardiovascular system such as dysrhythmias, myocardial infarction, and cardiovascular
collapse (Heard et al. 2008).
Mechanism of cocaine-induced toxicity is complex and involves simultaneous
stimulation on multiple targets, including neurotransmitter transporters and voltagedependent ion channels (Heard et al. 2008). Generally, in the central nervous system,
cocaine blocks the reuptake of neurotransmitters such as dopamine and serotonin, which
leads to the accumulation of these neurotransmitters in synaptic cleft and continuous
stimulation on dopamine and serotonin receptors. Stimulation on these receptors has been
reported to contribute to cocaine-induced seizures (Lason 2001). In the peripheral system,
cocaine blocks the reuptake of norepinephrine, which leads to constriction of blood vessels,
increased heart rate and elevated blood pressure. In addition, cocaine also blocks sodium
channels in the cells of the heart, resulting in conduction delays and dysrhythmias
(Gillespie 2006).
Current pharmacological therapies for cocaine intoxication include modulation of
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-aminobutyric acid (GABA) system, such as GABA receptor agonists (e.g.
benzodiazepines), and N-methyl D-aspartate (NMDA) -glutamate receptor system, such as
NMDA receptor antagonists (Heard et al. 2008). Although some studies using GABAA
receptor agonist showed beneficial outcome in attenuating cocaine-induced seizures and
death in mice (Gasior et al. 2000), it is difficult for these medications to fully block cocaineinduced effects by focusing on only one target of cocaine (Schindler et al. 2012). In
addition, norcocaine, a metabolite of cocaine, can be metabolized to generate Nhydroxynorcocaine and norcocaine nitroxide, which is believed to be associated with
cocaine-induced hepatotoxicity (Ndikum-Moffor et al. 1998). Another metabolite
benzoylecgonine has more vasoconstrictive effects than cocaine itself, by a mechanism
involving calcium channels (Madden et al. 1995). Norcocaine and benzoylecgonine, may
be present at high concentrations when a patient visits an emergency department (Connors
et al. 2013). The efficacy of above mentioned medications on reducing toxicity induced by
these metabolites remains unknown (Connors et al. 2013). Therefore, these approaches
have not been proven effective yet.
Alternatively, cocaine-metabolizing enzymes have shown promising results for
anti-cocaine treatment. Rather than targeting the pharmacological effects of cocaine, the
enzymes accelerate the metabolism of cocaine, and thus eliminate subsequent toxic effects
of cocaine. Examples of these enzymes include cocaine hydrolases (CocHs), which are
human butyrylcholinesterase (BChE) mutants that efficiently hydrolyze cocaine to
generate physiologically inactive metabolite ecgonine methyl ester (EME) and benzoic
acid (Connors et al. 2013). One of our previously designed CocHs, i.e. CocH1 (the
A199S/S287G/A328W/Y332G mutant of human BChE), efficiently catalyzes the
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hydrolysis of cocaine (Pan et al. 2005), norcocaine (Zhan et al. 2014), cocaethylene (Hou
et al. 2014) and benzoylecgonine (Chen et al. 2016). In further animal studies, we have
compared the effects of human serum albumin-fused CocH1 (CocH1-HSA), and diazepam,
which is a GABA agonist, in reversing cocaine toxicity in male rats. Although 5 mg/kg
diazepam attenuated cocaine-induced hyperactivity and slowed down the elimination of
cocaine and its metabolites, 5 mg/kg CocH1-HSA immediately aborted cocaine-induced
hyperactivity and completely removed cocaine from the blood in male rats, suggesting
CocH1-HSA was more effective than diazepam (Zhang et al. 2017). Overall, these studies
indicate the clinical potential of CocH1 for the treatment of cocaine overdose.
Increasing evidence has suggested gender differences in substance use disorders
(Brady et al. 1999, Becker et al. 2001, Elman et al. 2001). In animal models, significantly
less cocaine concentration in plasma was required to produce cardiovascular toxic effects
in female rats than in male rats (Morishima et al. 1993). In human studies, women progress
from casual drug use to dependence more rapidly, experiencing higher levels of craving
and relapse during periods of abstinence, taking larger amounts of the substance during
bouts of relapse. Women entering drug abuse treatment programs generally have a more
severe addiction syndrome (Bobzean et al. 2014). Therefore, the higher sensitivity to
addictive drug in females makes it more challenging for antagonizing cocaine in females
than in males.
In the present study, we aim to evaluate the effectiveness of CocH1-HSA at a dose
of 5 mg/kg for cocaine overdose treatment in both male and female rats. For this purpose,
we first compared the locomotor activities of male and female rats receiving a single dose
of 20 mg/kg (i.p.) cocaine, and demonstrated gender difference in the behavioral response
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to cocaine. Next, we determined the pharmacokinetic profiles of CocH1-HSA and
metabolic profiles of cocaine in both genders. Male and female rats were later compared
to evaluate the effectiveness of the enzyme in protecting and rescuing the animals from a
lethal dose of cocaine (180 mg/kg, LD100). The data obtained clearly demonstrated that
CocH1-HSA was equally active in both genders, suggesting the clinical potential of
CocH1-HSA in treating cocaine overdose for both genders.
2.2
2.2.1

Materials and Methods
Materials

CocH1 (the A199S/F227A/S287G/A328W mutant of human BChE) truncated after
amino acid 529 was fused with human serum albumin (HSA). The protein was expressed
by lentivirus-transfected CHO-S cells, and was purified by using AlbuPure affinity
chromatography on an ÄKTA Avant 150 system (GE Healthcare Life Sciences, Pittsburgh,
PA). Purified CocH1-HSA was stored in buffer (50 mM HEPES, 20% sorbitol, 1 M
glycine, pH 7.4) at − 80 °C before use.
Cocaine, EME, benzoylecgonine, and norcocaine were provided by the National
Institute on Drug Abuse (NIDA) Drug Supply Program (Bethesda, MD). Deuterated
cocaine, EME, benzoylecgonine were purchased from Cerilliant (Round Rock, TX). [3H](-)-cocaine (50 Ci/mmol) was purchased from PerkinElmer (Waltham, MA). AlbuPure was
ordered from ProMetic (Rockville, MD). All other chemicals were purchased from Thermo
Fisher Scientific (Waltham, MA) or Sigma-Aldrich (St. Louis, MO).
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2.2.2

Animals

Male and female Sprague-Dawley rats (220–250 g) were ordered from Harlan
(Harlan, Indianapolis, IN), and housed initially as one or two rats per cage. All rats were
kept at room temperature of 21–22°C, allowing ad libitum access to food and water.
Animal housing areas were maintained on a 12 h light/12 h dark cycle, with lights on at
8:00 a.m. Experiments were performed in accordance with the Guide for the Care and Use
of Laboratory Animals as adopted and promulgated by the National Institutes of Health.
The animal protocol was approved by the IACUC (Institutional Animal Care and Use
Committee) at the University of Kentucky.
2.2.3

Blood sample collection and analysis

To measure plasma enzyme concentration, blood samples (75 l) were collected
from saphenous vein using heparin-treated capillary tubes at various time-points after
enzyme administration. Collected blood samples were centrifuged for 15 min at a speed of
5000 g, and separated plasma was kept at 4°C before analysis. A sensitive radiometric
assay as described before (Brimijoin et al. 2002) was performed to measure enzyme
concentration in plasma. Briefly, 10 l of plasma sample was mixed with 140 l of 0.1 M
phosphate buffer (pH = 7.4). 50 l of 400 M [3H]-(-)-cocaine was added to the mixture
to initiate enzymatic reaction. The reaction proceeded at room temperature, and was
stopped by adding 200 l of 0.1 M hydrochloric acid. The radioactive product benzoic acid
was extracted by toluene for scintillation counting. The enzyme concentration ([E]) was
calculated based on the equation: [E] = Vmax/kcat, where Vmax is the maximum rate the
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enzymatic reaction can achieve, kcat is the turnover number of the enzyme. Enzyme kinetic
parameters were obtained from our previous study (Yang et al. 2010).
To determine the concentrations of cocaine and its metabolites in whole blood, rat
blood samples (75 l) were collected from saphenous vein using heparin-treated capillary
tubes at various time-points after cocaine administration, and were mixed immediately with
100 µL of 0.1% formic acid containing 250 µM paraoxon. Blood samples were stored at 80 °C before use. For analysis, thawed blood sample was mixed with 500 µl of 4% formic
acid and 75 µL of 100 nM internal standards. The mixture was then subject to a one-step
solid-phase extraction (SPE) using mixed cation exchange model solid phase extraction
cartridges (Oasis MCX 1 cc Vac Cartridge, 10 mg) purchased from Waters (Milford, MA).
Briefly, the loaded sample was washed twice with 1 mL methanol, followed by elution
using 1 mL methanol/7.5% ammonium hydroxide (95:5, v/v).
A quantitative LC-MS/MS assay described in our previous study (Chen et al. 2017)
was applied to quantify cocaine and its metabolites in blood samples. Extracted samples
were evaporated and re-suspended in 0.1% formic acid before loading to a Shimadzu
HPLC system (Shimadzu, Kyoto, Japan), consisting of a DGU-20A/3R degasser, LC-20
AD binary pumps, CBM-20A controller, and SIL-20A/HT auto sampler. Mobile phase A
consisted of 0.1% formic acid and mobile phase B consisted of 0.1% formic acid:
acetonitrile (10:90, v/v). Samples were loaded to an Atlantis T3 (100 Å, 3 μm, 2.1 mm X
150 mm I.D) column (Waters, Milford, MA) and were eluted by gradient. AB SCIEX
tripleTOF™ 5600 (AB SCIEX, Redwood City, CA) was applied in positive ion and high
sensitivity mode for analysis.
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2.2.4

Experiment design

Locomotor activity in male and female rats

Cocaine-induced locomotor activity in male and female rats were compared. On
the test day, rats (n = 8 for each group) were placed in high-density, non-porous plastic
chambers (50-cm L x 50-cm W x 38-cm H) in a quiet room and allowed to acclimate. One
hour following acclimation, rats were i.p. administered with saline or 20 mg/kg cocaine,
and were immediately returned to the test chambers. The distance traveled every 5 minutes
were tracked and recorded for 2 hrs using ANY-maze video tracking system (San Diego
Instruments, San Diego, CA). Upon completion of the tests, animals were returned to their
home cages.
Pharmacokinetic profiles of cocaine in male and female rats.

To determine if cocaine PK profiles contribute to the gender difference in response
to cocaine, both male and female rats received the same dose of cocaine administration. To
more reasonably mimic cocaine overdose conditions, a high dose of cocaine was used in
this study. In our preliminary study on cocaine-induced toxicity in male rats, i.p.
administration of 60 mg/kg cocaine induced convulsion in six, and death in two out of eight
rats. Therefore, we decided to determine the metabolic profiles of cocaine in survived rats
receiving 60 mg/kg cocaine. In this study, cocaine was i.p. administered to rats (n = 4), and
blood samples were collected at different time points after cocaine administration. Cocaine
and its metabolites concentrations in blood were determined as described as above.
Pharmacokinetic profiles of CocH1-HSA in male and female rats.
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To evaluate the effectiveness of CocH1-HSA in male and female rats, the PK
profiles of CocH1-HSA in both genders were compared first. Rats were i.v. injected via
tail vein with purified CocH1-HSA at 0.075 mg/kg (n = 4), 1 mg/kg (n =4), or 5 mg/kg (n
= 6) for each gender. Blood samples were collected at different time points after enzyme
administration. Enzyme concentration in plasma was determined as described above.
Protection and rescue experiments in male and female rats.

To compare the effectiveness of CocH1-HSA in treating cocaine-induced toxicity
in male and female rats, protection and rescue experiments were conducted in both genders.
In these studies, cocaine-induced acute toxicity was quantified by the occurrence of
convulsion and death. Convulsion was defined as loss of righting posture, and recovery
was characterized as the normal righting reflex (Ko et al. 2007). In protection experiment,
rats were pre-treated with 5 mg/kg CocH1-HSA (i.v.). 1 min following enzyme
administration, rats were i.p. administered with 180 mg/kg cocaine. In rescue experiment,
rats were i.p. administered with 180 mg/kg cocaine. At the onset of convulsion, rats were
immediately i.v. administered with 5 mg/kg CocH1-HSA via tail vein. Blood samples were
collected at different time points after cocaine administration. Cocaine and its metabolites
concentrations in blood were quantified as described above.
2.2.5

Pharmacokinetic and statistical analysis

Two-sample t-test was performed to compare the total distance traveled of male
and female rats in response to saline or cocaine. Two-way mixed-design analysis of
variance (ANOVA) was performed to compare the time-dependent concentration profiles
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of CocH1-HSA, cocaine, and cocaine metabolites in male and female rats, with gender as
the between-subjects variable and time as the within-subjects variable. All statistical tests
were performed using SPSS 23.0 for Mac (SPSS Inc., Chicago, IL). A p < 0.05 was
considered statistically significant. Noncompartmental analysis was performed using
Phoenix WinNonlin (Certara, Princeton, NJ) to determine the pharmacokinetic parameters
of CocH1-HSA in male and female rats.
2.3

Results

2.3.1

Gender difference in behavior response to cocaine

Cocaine-induced locomotor activities in male and female rats were displayed in
Figure 2.1, Male and female rats showed similar baseline activity after saline injection. No
statistical difference was observed between saline-treated male and female rats for total
locomotor counts (p = 0.072). However, following 20 mg/kg i.p. administration, cocaine
induced hyperactivity in both male and female rats for at lease two hours. Females showed
significantly higher cocaine-stimulated total locomotor counts than males (p = 0.002).
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Figure 2.1 Cocaine-induced locomotor activity in male and female rats.
Rats (n = 8 for each gender) were i.p. administered with either saline or 20 mg/kg cocaine
at 0 min. Time-course of locomotor activity (distance traveled per 5 min) produced by
cocaine (A). Total distance (m) traveled in two hours after administration of saline or
cocaine (B). Data are shown as mean  SEM. p < 0.05 was considered significantly
different.
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2.3.2

Metabolic profiles of cocaine in male and female rats

Next, we studied the PK profiles of cocaine in both genders. The blood
concentration-time profiles of cocaine, ecgonine methyl ester (EME), benzoylecgonine
(BE), and norcocaine (NC) were depicted in Figure 2.2. In both genders, cocaine was
primarily metabolized via three major pathways: (1) hydrolysis at the benzoyl ester group
to generate EME and benzoic acid, (2) hydrolysis at the methyl ester group to generate BE
and methanol, and (3) N-demethylation to generate NC. Cocaine was eliminated slightly
slower in female rats in terminal phase, but no significant difference was observed (p =
0.247) in the concentration-time profiles. EME concentration in female rats was slightly
higher than that in male rats, although not significant (p = 0.06). In both male and female
rats, COC and NC blood concentrations reached the peaks at ~30 min after administration
and declined subsequently. In contrast, BE and EME reached their peaks after 30 min and
were eliminated slowly. The peak concentration of cocaine was ~10 M, and BE
concentration was much higher than other compounds after ~30 min. These results indicate
that PK of cocaine does not explain the gender difference in behavior response to cocaine.
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Figure 2.2 Pharmacokinetic profiles of cocaine in male and female rats.
Rat (n = 4 for each gender) were i.p. administered with 60 mg/kg cocaine. Time-dependent
blood concentrations of cocaine, EME, benzoylecgonine, and norcocaine are shown in the
figures. Data are shown as mean  SD.
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2.3.3

Pharmacokinetic profiles of CocH1-HSA in male and female rats

Plasma concentration-time profiles of CocH1-HSA in male and female rats were
shown in Figure 2.3. Rats received i.v. administration of CocH1-HSA at different dose
levels. Two-way mixed-design ANOVA was performed to compare plasma concentrationtime profiles in male and female rats. No statistically significant difference was observed
between male and female rats under all dose conditions. The PK parameters determined
using noncompartmental analysis were summarized in Table 2.1. Male and female rats had
similar Cmax and terminal half-life (~8 h) among three dose levels. AUC was linearly
dependent on dose, suggesting linear PK of CocH1-HSA in both male and female rats
within this dose range. Taken together, there was no significant difference in the PK
profiles of CocH1-HSA in both genders, indicating that CocH1-HSA would be similarly
active in hydrolyzing cocaine in both male and female rats.
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Figure 2.3 Time-dependent plasma concentrations of CocH1-HSA in male and female rats.
Rats received an i.v. administration of CocH1-HSA at 0.075 mg/kg (n = 4), 1 mg/kg (n =
4), or 5 mg/kg (n = 6). Data are shown as mean  SD.
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Table 2.1 Pharmacokinetic parameters of CocH1-HSA in male and female rats.
Rat Gender

M

F

M

F

M

F

0.075

0.075

1.00

1.00

5.00

5.00

T1/2 (hr)

7.9 ± 1.3

8.0 ± 1.2

5.7 ± 1.0

5.8 ± 1.2

5.8 ± 0.9

6.3 ± 1.4

Cmax (mg/L)

1.5 ± 0.3

1.4 ± 0.1

19.2 ± 2.8

18.7 ± 1.6

103.8 ± 7.3

101.3 ± 4.4

AUC0-∞ (mg*hr/L)

14.5 ± 0.3

14.1 ± 0.6

178.0 ± 19.5

185.2 ± 15.9

989.1 ± 70.8

961.2 ± 73.5

CocH1-HSA
(mg/kg)
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2.3.4

Protection and rescue effects of CocH1-HSA in male and female rats

To mimic a serious overdose scenario, we used 180 mg/kg cocaine, which is LD100
of cocaine in rats, to evaluate the protection and rescue effects of CocH1-HSA. According
to the data revealed in Table 2.2, 180 mg/kg (i.p.) cocaine alone induced convulsion and
death in all male and female rats. Furthermore, compared to male rats, female rats
developed convulsion and died earlier than male rats. Female rats developed convulsion at
~1.5 min, and died at ~3.4 min. In contrast, male rats developed convulsion at ~2.8 min,
and died at ~4.1 min. This is in consistent with our previous observation that female rats
were more sensitive to cocaine than male rats.
In the protection experiment, all male and female rats were successfully protected
by 5 mg/kg i.v. injected CocH1-HSA against 180 mg/kg cocaine. None of the rats
developed convulsion, and none of them died. As seen in Figure 2.4A, cocaine was rapidly
and completely hydrolyzed to generate EME since the first time point, suggesting that
CocH1-HSA efficiently accelerated the metabolism of cocaine once cocaine was absorbed
in the circulating system. Norcocaine was also rapidly eliminated and norcocaine level
reached the quantification limit since the first time point, suggesting CocH1-HSA also
accelerate the hydrolysis of norcocaine. In addition, at all time points, EME level was much
higher than the corresponding cocaine, norcocaine, and benzoylecgonine levels.
In further rescue experiments, similar to the observation in the control group,
female rats developed convulsion earlier than male rats. However, 5 mg/kg CocH1-HSA
successfully rescued all male and female rats from 180 mg/kg cocaine. All rats
discontinued convulsion within 1 min of CocH1-HSA administration, and recovered
quickly. The rescue effects of CocH1-HSA were consistent with blood concentration-time
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profiles shown in Figure 2.4B. After enzyme administration, cocaine was rapidly
hydrolyzed to generate the physiologically inactive EME, which explains why all rats
recovered quickly. In addition, similar to the protection experiment, the blood levels of
cocaine, norcocaine, and benzoylecgonine were much lower than the corresponding EME
levels at all time points.
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Table 2.2 Effects of CocH1-HSA on cocaine (180 mg/kg, i.p.)-induced convulsion and
lethality in male and female rats.
Enzyme

Enzyme

Rat sex Method

Dose

#

(route)

of Time after cocaine injection (min)

rats

Convulsion Death

Recoveryd

None

0

Male

Control (i.v.) a

10

2.78 ± 1.03

4.07 ±1.87

N.A.e

CocH1-HSA

5 mg/kg

Male

Protection (i.v.) b

10

N.A. e

N.A. e

N.A. e

Rescue (i.v.) c

10

2.82 ± 1.92

N.A. e

4.20 ± 1.91

None

0

Female Control (i.v.) a

12

1.53 ± 0.52

3.37 ± 0.60

N.A. e

CocH1-HSA

5 mg/kg

Female Protection (i.v.) b

8

N.A. e

N.A. e

N.A. e

10

1.87 ± 0.50

N.A. e

3.10 ± 0.69

Rescue (i.v.) c
a

Control experiment was performed by i.p. administration of 180 mg/kg cocaine only

b

Protection experiment was performed by pretreatment with rats with 5 mg/kg CocH1-

HSA (i.v.) 1 min before 180 mg/kg cocaine (i.p.)
c

Rescue experiment was performed by first administration of 180 mg/kg cocaine (i.p.),

followed by 5 mg/kg CocH1-HSA (i.v.) at the onset of cocaine-induced convulsion
d

The time (starting from cocaine administration) when rats were fully recovered from

cocaine-induced convulsion (occurrence of righting reflex)
e

Not applicable (N.A.)
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(A)

(B)

Figure 2.4 Time-dependent blood concentrations of cocaine and its metabolites in rats.
Rats (n = 4) were pretreated with 5 mg/kg CocH1-HSA (i.v.) 1 min before i.p.
administration of 180 mg/kg cocaine (A). Rats (n = 4) were first i.p. administered with 180
mg/kg cocaine. 5 mg/kg CocH1-HSA (i.v.) was administered after the onset of cocaineinduced convulsion (B). Blood samples were collected only after CocH1-HSA
administration.
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2.4

Discussion and Conclusions
BChE has been investigated for its anti-cocaine potential since more than two

decades ago (Gorelick 1997, Lynch et al. 1997). Significant cocaine-induced toxic effects
were observed in BChE-knockout mice, compared to BChE+/+ mice (Duysen et al. 2008).
However, the major limitation of BChE is its poor catalytic activity against cocaine (KM
~4.5 M, kcat ~4.1 min-1), leading to the exploration of highly efficient BChE mutants (Sun
et al. 2002).
Recently, through structure- and mechanism-based computational modeling and
simulation, CocH1 was rationally designed to have not only ~1000-fold enhanced catalytic
efficiency in hydrolyzing (-)-cocaine, but also considerably enhanced activities in
hydrolyzing the toxic metabolites of cocaine, namely, norcocaine, cocaethylene, and
benzoylecgonine (Pan et al. 2005, Hou et al. 2014, Zhan et al. 2014, Chen et al. 2016). In
rat studies, albumin-fused CocH1 dose-dependently rescued rats from cocaine intoxication,
and rightward shifted the dose-response curve for seizure induced by cocaine (Brimijoin et
al. 2008). In the same study, rats were i.v. administered with 3.5 mg/kg cocaine, followed
by saline or 10 mg/kg i.v. administered Albu-CocH1. Albu-CocH1 significantly reduced
brain cocaine concentration at approximately four-fold, demonstrating the ability of
enzyme to eliminate cocaine from brain (Brimijoin et al. 2008). Overall, these studies
indicate the potential of CocH1 for the treatment of cocaine overdose.
Extensive studies have reported gender difference in the response to cocaine (Brady
et al. 1999, Becker et al. 2001, Elman et al. 2001). In the present study, despite the similar
basal activity, female rats developed greater hyperactivity than male rats following a single
dose (20 mg/kg, i.p.) of cocaine. Likewise, it has been reported that female rats were more
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sensitive to cocaine-induced psychomotor stimulation and rewarding effects (Festa et al.
2004). The mechanism behind the gender difference was investigated. In a study reported
by Bowman et al, the gender difference in the metabolism of cocaine was studied to
determine the factors that contributed to the greater behavioral sensitivity of females to
cocaine. They reported no significant difference in the brain and plasma levels of cocaine
in male and female rats following 15 mg/kg i.p. cocaine administration (Bowman et al.
1999), which is consistent with our observation. In the present study, no significant
difference in blood cocaine concentration was observed between male and female rats.
As PK of cocaine could not explain the gender difference in response to cocaine,
increasing effort has been focused on studying the biological basis between male and
female. For example, it has been found that male rats had overproduction of dopamine D1
receptors in nucleus accumbens (Andersen et al. 1997), and female rats had greater striatal
dopamine release and re-uptake than male rats (Festa et al. 2004). In addition, Sell et al
found that female rats showed different behavioral response to cocaine within different
stages of estrous cycle, and ovariectomized (OVX) female rats implanted with ovarian
hormone (i.e. estrogen) displayed enhanced activity against cocaine than OVX female rats,
indicating the contribution of estrogen to the increased sensitivity in female rats (Sell et al.
2000). The effects of estrogen on the dopamine activity were further investigated. Zhang
et al reported that cocaine greatly inhibits the firing of ventral tegmental area (VTA)
dopamine neurons during proestrus, when estrogen level was higher. They concluded that
estrogen regulated dopamine neuron firing activity in VTA in female rats, thus contributing
to the gender differences in response to cocaine (Zhang et al. 2008).
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Since no significant difference in cocaine blood level was observed in male and
female rats, a cocaine hydrolyzing enzyme that alters the PK of cocaine is possibly an
equally effective anti-cocaine therapy for both genders. In the present study, we first
demonstrated that there was no significant difference in the PK profiles of CocH1-HSA
between male and female rats, suggesting similar capability of CocH1-HSA in hydrolyzing
cocaine in both genders. In addition, CocH1-HSA displayed linear pharmacokinetics in
both male and female rats, suggesting little effect of target-mediated drug disposition
(TMDD). CocH1-HSA exhibited ~8 h elimination half-life for three dose conditions in
both genders.
However, enhanced sensitivity to cocaine makes it challenging for us to treat
cocaine overdose in females. In the overdose scenario, the endogenous cocainemetabolizing enzymes will be saturated by high levels of cocaine (Rosenberg et al. 1981),
leading to slower elimination of cocaine, and cocaine will be remained at high level in the
body. Since females are more sensitive to cocaine-induced effects, the high level of cocaine
in the body could make females have narrower time window to rescue. In this study, we
evaluated the effects of CocH1-HSA in rats receiving lethal dose (LD100) of cocaine, which
mimics the extreme condition. The onset time of convulsion/seizure, which is a major
determinant of cocaine-related lethality was recorded. According to our observations,
under the extreme condition where rats received a lethal dose (LD100) of cocaine, all the
male and female rats in control group developed convulsion/seizures and died within ~4
minutes after cocaine administration. Female rats experienced convulsion and death a little
earlier than male rats. In comparison, while female rats had narrower time window for
rescue, CocH1-HSA was similarly effective in rescuing both male and female rats against
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lethal dose of cocaine. 5 mg/kg CocH1-HSA rescued all the male and female rats by rapidly
converting cocaine to physiologically inactive metabolite EME. In addition to cocaine,
CocH1-HSA also rapidly decreased blood levels of the toxic metabolites norcocaine and
benzoylecgonine, suggesting its effects in reducing toxic effects induced by these
metabolites. Taken together, this enzyme therapy is promising for cocaine overdose
treatment in both genders.
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CHAPTER 3. AN EFFICIENT COCAINE HYDROLASE TO TREAT TOXICITY
RESULTED FROM SIMULTANEOUS USE OF ALCOHOL AND COCAINE
3.1

Introduction
Concurrent use of alcohol and cocaine is one of the most common abused drug

combinations (Lindholm et al. 2001). More than 70% of cocaine users concurrently
consume alcohol during their binges (Snenghi et al. 2018). Greater euphoric effects have
been reported when alcohol and cocaine were combined than that when cocaine was
administered alone, which may explain the high rate of combinational use of alcohol and
cocaine (Lindholm et al. 2001). Concurrent use of alcohol and cocaine also helps cocaine
users avoid cocaine and its metabolites-induced side effects, such as headaches (Dean et
al. 1992). These effects may encourage cocaine abusers to take a larger amount of drugs,
thus leading to high risk of cocaine intoxication (McCance-Katz et al. 1998).
Several studies have demonstrated that alcohol enhanced the toxicity of cocaine
(Busse et al. 2003). For example, simultaneous administration of alcohol and cocaine
increased heart rate in rats than that when either drug was administered alone (McCanceKatz et al. 1998). Increased risk of cerebral infarction, intracranial hemorrhage, myocardial
infarction, and cardiac arrhythmias results from combination of alcohol and cocaine was
also reported in human (Farooq et al. 2009). Taken together, combinational use of alcohol
and cocaine may have a higher risk than cocaine use alone (Andrews 1997).
Cocaine reacts with alcohol to generate cocaethylene (CE) by nonspecific liver
carboxylesterase (Dean et al. 1992). CE rapidly enters the brain and blocks the reuptake of
dopamine, producing the stimulant effects that are similar to that induced by cocaine
(Wetzel et al. 2014). CE has a longer elimination half-life (~150 minutes) in human,
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compared to ~90 minutes of cocaine, which may explain the prolonged euphoric effects
after concurrent use of alcohol and cocaine (McCance-Katz et al. 1998). In addition, CE
was found to be more lethal than cocaine in mice (Hearn et al. 1991). Through testing the
dose-dependent toxicity of cocaine and cocaethylene in Swiss Webster mice, Hearn et al.
determined LD50 of cocaine and cocaethylene, revealing a significantly lower LD50 of
cocaethylene (LD50 = 63.8 mg/kg in male mice) compared to cocaine (LD50 = 93.0 mg/kg
in male mice) (Hearn et al. 1991).
The formation of norcocaethylene (NCE) is also alcohol-dependent (shown in
Figure 3.1). There are at least two pathways responsible for the formation of NCE. One
potential pathway involves the transesterification of cocaine to generate CE, followed by
N-demethylation of CE to NCE. Another pathway involves N-demethylation of cocaine to
generate norcocaine, followed by transesterification of NC to NCE (Dean et al. 1992).
However, the toxicity of NCE has not been determined in previous studies.
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Figure 3.1 Schematic representation of cocaine and its toxic metabolites produced in the
concurrent use of cocaine and alcohol.
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Human BChE mutants has been designed with at least 1000-fold improved catalytic
efficiency against cocaine (Pan et al. 2005, Zheng et al. 2008, Xue et al. 2013, Zheng et
al. 2014). These BChE mutants also have considerably improved catalytic activities against
cocaethylene. In previous in vitro studies, compared to wild-type BChE, CocH1 (the
A199S/S287G/A328W/Y332G mutant of human BChE) has a 517-fold improved catalytic
efficiency against cocaethylene, and CocH3 (the A199S/F227A/S287G/A328W/Y332G
mutant of human BChE) has an 861-fold improved catalytic efficiency against
cocaethylene (Hou et al. 2014), indicating their effectiveness in reversing alcohol and
cocaine-induced toxicity. CocH5 (the A199S/F227A/P285A/S287G/A328W/Y332G
mutant of human BChE) is the most efficient enzyme reported so far, with further enhanced
activity against cocaine compared to CocH1 and CocH3 (Zheng et al. 2014). We expect
CocH5 to be more efficient in reversing alcohol-potentiated cocaine toxicity.
In this study, a six-mutated Fc region of human IgG1 was fused to CocH5 to yield
CocH5-Fc(6M). The aim of this study is to investigate efficiency of CocH5-Fc(6M) in
reversing alcohol and cocaine-induced toxicity in rats. For this purpose, we first studied
the metabolic profiles of cocaine in rats with or without co-administration of alcohol. Then,
we compared the lethality of cocaine and its toxic metabolites in mice, demonstrating the
contribution of cocaethylene and norcocaethylene to alcohol-potentiated cocaine toxicity.
Later, we evaluated the effectiveness of CocH5-Fc(6M) in protecting and rescuing rats
from a lethal dose of cocaine (180 mg/kg, LD100) with co-administration of alcohol (1 g/kg).
CocH5-Fc(6M) accelerated the hydrolysis of not only cocaine, but also norcocaine,
benzoylecgonine, cocaethylene, norcocaethylene in rats. The data obtained clearly
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demonstrated that CocH5-Fc(6M) was efficient in treating toxicity from simultaneous use
of alcohol and cocaine.
3.2

Materials and Methods

3.2.1

Materials

CocH5 (the A199S/F227A/P285A/S287G/A328W/Y332G mutant of human BChE)
truncated after amino acid 529 was fused with six-mutated Fc region of human IgG. The
protein was expressed by lentivirus-transfected CHO-S cells, and was purified by using
protein A affinity chromatography on an ÄKTA Avant 150 system (GE Healthcare Life
Sciences, Pittsburgh, PA). Purified CocH5-Fc(6M) was stored in buffer (50 mM HEPES,
20% sorbitol, 1 M glycine, pH 7.4) at − 80 °C before use.
Cocaine, EME, benzoylecgonine, and norcocaine were provided by the National
Institute on Drug Abuse (NIDA) Drug Supply Program (Bethesda, MD). Deuterated
cocaine, EME, benzoylecgonine were purchased from Cerilliant (Round Rock, TX). [3H](-)-cocaine (50 Ci/mmol) was purchased from PerkinElmer (Waltham, MA). Protein A was
ordered from ProMetic (Rockville, MD). All other chemicals were purchased from Thermo
Fisher Scientific (Waltham, MA) or Sigma-Aldrich (St. Louis, MO).
3.2.2

Animals

Male Sprague-Dawley rats (220–250 g) were ordered from Harlan (Harlan,
Indianapolis, IN), and housed initially as one or two rats per cage. Male Swiss Webster
mice (30-35 g) were ordered from Charles River Laboratories (Wilmington, MA). All
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animals were kept at room temperature of 21–22°C, allowing ad libitum access to food and
water. Animal housing areas were maintained on a 12 h light/12 h dark cycle, with lights
on at 8:00 a.m. Experiments were performed in accordance with the Guide for the Care and
Use of Laboratory Animals as adopted and promulgated by the National Institutes of
Health. The animal protocol was approved by the IACUC (Institutional Animal Care and
Use Committee) at the University of Kentucky.
3.2.3

Blood sample collection and analysis

To measure plasma enzyme concentration, blood samples (75 l) were collected
from saphenous vein using heparin-treated capillary tubes at various time-points after
enzyme administration. Collected blood samples were centrifuged for 15 min at a speed of
5000 g, and separated plasma was kept at 4°C before analysis. A sensitive radiometric
assay as described before (Brimijoin et al. 2002) was performed to measure enzyme
concentration in plasma. Briefly, 10 l of plasma sample was mixed with 140 l of 0.1 M
phosphate buffer (pH = 7.4). 50 l of 400 M [3H]-(-)-cocaine was added to the mixture
to initiate enzymatic reaction. The reaction proceeded at room temperature, and was
stopped by adding 200 l of 0.1 M hydrochloric acid. The radioactive product benzoic acid
was extracted by toluene for scintillation counting. The enzyme concentration ([E]) was
calculated based on the equation: [E] = Vmax/kcat, where Vmax is the maximum rate the
enzymatic reaction can achieve, kcat is the turnover number of the enzyme. Enzyme kinetic
parameters were obtained from our previous study (Zheng et al. 2014).
To determine the concentrations of cocaine and its metabolites in whole blood,
blood samples (75 l) were collected from saphenous vein using heparin-treated capillary
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tubes at various time-points after cocaine administration, and were mixed immediately with
100 µL of 0.1% formic acid containing 250 µM paraoxon. Blood samples were stored at 80 °C before use. For analysis, thawed blood sample was mixed with 500 µl of 4% formic
acid and 75 µL of 100 nM internal standards. The mixture was then subject to a one-step
solid-phase extraction (SPE) using mixed cation exchange model solid phase extraction
cartridges (Oasis MCX 1 cc Vac Cartridge, 10 mg) purchased from Waters (Milford, MA).
Briefly, the loaded sample was washed twice with 1 mL methanol, followed by elution
using 1 mL methanol/7.5% ammonium hydroxide (95:5, v/v).
A quantitative LC-MS/MS assay described in our previous study (Chen et al. 2017)
was applied to quantify cocaine and its metabolites in blood samples. Briefly, extracted
samples were evaporated and re-suspended in 0.1% formic acid before loading to a
Shimadzu HPLC system (Shimadzu, Kyoto, Japan), consisting of a DGU-20A/3R degasser,
LC-20 AD binary pumps, CBM-20A controller, and SIL-20A/HT auto sampler. Mobile
phase A consisted of 0.1% formic acid and mobile phase B consisted of 0.1% formic acid:
acetonitrile (10:90, v/v). Samples were loaded to an Atlantis T3 (100 Å, 3 μm, 2.1 mm X
150 mm I.D) column (Waters, Milford, MA) and were eluted by gradient. AB SCIEX
tripleTOF™ 5600 (AB SCIEX, Redwood City, CA) was applied in positive ion and high
sensitivity mode for analysis.
3.2.4

Experimental design

Cocaine-induced toxicity in rats with or without co-administration of alcohol
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To evaluate the influence of alcohol on cocaine-induced toxicity in rats, rats were
i.p. administered with 40 mg/kg cocaine with or without co-administration of 1 g/kg (i.p.)
alcohol (20%, w/v). In our preliminary studies, this dose of alcohol (1 g/kg) did not induce
obvious side effects in rats, and cocaine dose higher than 40 mg/kg induced death in rats.
Therefore, we decided to use 40 mg/kg (i.p.) for cocaine administration and 1 g/kg (i.p.)
for alcohol administration in this study. Convulsion was defined as loss of righting posture
(Ko et al. 2007), and the time of convulsion was recorded.
Metabolic profiles of cocaine in rats with or without co-administration of alcohol

To determine the effects of alcohol on the metabolic profiles of cocaine, rats were
i.p. administered with 60 mg/kg cocaine, with or without co-administration of 1 g/kg (i.p.)
alcohol. Blood samples were collected at different time points after cocaine injection.
Cocaine and its metabolites concentrations in blood were quantified as described above.
Lethality of norcocaine and norcoacethylene in mice

To compare the acute toxicity of norcocaine and norcaethylene in mice, drugs were
i.p. administered to male Swiss Webster mice (n = 15 for each dose condition in each group)
at different dose levels. After injection, mice were placed in home cages and were observed
for lethality. Dose-dependent lethality was calculated by fitting the curves in Prism
(GraphPad, San Diego, CA). LD50 of norcocaine and norcocaethylene were compared to
previously reported results (Hearn et al. 1991).
Effects of CocH5-Fc(6M) on the metabolism of cocaine and its toxic metabolites in rat
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To evaluate the effectiveness of CocH5-Fc(6M) on the metabolic profiles of
cocaine in rat receiving simultaneous administration of cocaine and alcohol, rats were i.p.
administered with 1 g/kg alcohol (20%, w/v), followed by i.p. administration of 60 mg/kg
cocaine. At 30 min after cocaine injection, saline or 1 mg/kg CocH5-Fc(6M) was i.v.
administered to rats via tail vein. Blood samples were collected at different time points
after cocaine administration. Cocaine and its metabolites concentrations in blood were
quantified as described above.
Protection and rescue experiment in rats using CocH5-Fc(6M)

To compare the effectiveness of CocH5-Fc(6M) in treating cocaine-induced
toxicity in rats, protection and rescue experiments were conducted. In these studies,
cocaine-induced acute toxicity was quantified by the occurrence of convulsion and death.
Convulsion was defined as loss of righting, and recovery was characterized as the normal
righting reflex (Ko et al. 2007). In protection experiment, rats were pre-treated with 1
mg/kg CocH5-Fc(6M) (i.v.). 1 min following enzyme administration, rats were i.p.
administered with 1 g/kg alcohol and 180 mg/kg cocaine. In rescue experiment, rats were
i.p. administered with 1 g/kg alcohol and 180 mg/kg cocaine. At the onset of convulsion,
rats were immediately i.v. administered with 1 mg/kg CocH5-Fc(6M) via tail vein. Blood
samples were collected at different time points after cocaine administration. Cocaine and
its metabolites concentrations in blood were quantified as described above.
Statistical analysis

Two-way mixed-design analysis of variance (ANOVA) was performed to compare
the time-dependent concentration profiles of cocaine and its metabolites in rats, with
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treatment as the between-subjects variable and time as the within-subjects variable. All
statistical tests were performed using SPSS 23.0 for Mac (SPSS Inc., Chicago, IL). p <
0.05 was considered statistically significant.
3.3

Results

3.3.1

Alcohol-enhanced cocaine toxicity in rats

The effect of alcohol on cocaine-induced toxicity was shown in Table 3.1.
According to our observation, 40 mg/kg cocaine alone did not induce convulsion in rats.
However, when 1 g/kg alcohol was simultaneously administered with 40 mg/kg cocaine to
rats, six out of eight rats developed convulsion, with a mean convulsion onset time at ~4.9
min. This observation indicates that simultaneous administration of alcohol enhanced
cocaine-induced toxicity.
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Table 3.1 Effects of alcohol on cocaine-induced convulsion in rats.
Cocaine Dose

Alcohol Dose

Convulsion time after

Percentage of Rats

(i.p.)

(i.p.)

cocaine injection

Developing Convulsion

(min)
40 mg/kg

N.A.

N.A.

0%

40 mg/kg

1 g/kg

4.9 ± 1.3

75 %

45

3.3.2

Alcohol-altered PK profiles of cocaine in rats

In order to investigate the mechanism of alcohol-enhanced cocaine toxicity, the
metabolic profiles of cocaine with or without co-administration of alcohol were studied in
rats. Figure 3.2 displays time-dependent concentration profiles of cocaine and its
metabolites in rats following 60 mg/kg i.p. cocaine, with or without simultaneous i.p.
administration of 1 g/kg alcohol. According to our observation, in rats receiving cocaine
administration alone, cocaine (COC) was mainly metabolized to generate ecgonine methyl
ester (EME), norcocaine (NC), and benzoylecgonine (BE). On the other hand, in addition
to generating these compounds, COC was also metabolized to form cocaethylene (CE) and
norcocaethylene (NCE) in rats receiving co-administration of cocaine and alcohol. There
was no significant difference in blood concentrations of COC, EME, and NC between two
groups (p = 0.664, 0.725, and 0.956, respectively). Although not significant, BE blood level
was slightly lower in rats receiving both cocaine and alcohol (p = 0.101). The lower BE
level may due to the fact that alcohol inhibits liver carboxylesterase, which is the enzyme
responsible for the formation of BE (Dean et al. 1991). These results demonstrated that
while not changing cocaine concentrations in blood, alcohol altered the metabolic profiles
of cocaine in rats.
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Figure 3.2 Metabolic profiles of cocaine in rats with or without simultaneous
administration of alcohol.
Time-dependent blood concentrations of cocaine (A), EME (B), benzoylecgonine (C),
norcocaine (D), cocaethylene (E), and norcocaethylene (F) in rats. Rats (n = 4 for each
group) were received 60 mg/kg cocaine (i.p.) with or without co-administration of 1 g/kg
alcohol (i.p.). Data are shown as mean  SEM.
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3.3.3

Comparison of toxicity of cocaine, norcocaine, cocaethylene, and norcocaethylene

To investigate the contribution of CE and NCE to alcohol-enhanced toxicity, the
lethality of cocaine and its metabolites were compared in male Swiss Webster mice. It has
been reported that 200 mg/kg (i.v.) EME or 250 mg/kg (i.v.) benzoylecgonine produced no
observable pharmacological effects in rats (Mets et al. 1995). In contrast, in our
preliminary experiments, 180 mg/kg cocaine (i.p.) caused 100% death in rats, suggesting
less toxicity of BE and NC compared to cocaine. Therefore, we did not evaluate the
lethality of EME and benzoylecgonine. Instead, the lethality of cocaine, norcocaine,
cocaethylene, and norcocaethylene was compared in this study.
Dose-lethality curves of NC and NCE in Swiss Webster mice were shown in Figure
3.3. Calculated LD50 values were summarized in Table 3.2. In comparison to the reported
LD50 (Hearn et al. 1991) of COC (~93.0 mg/kg) and CE (~63.8 mg/kg) in male mice, in
the present study using the same strain of mice, calculated LD50 for NC was ~49.7 mg/kg,
while for NCE was ~39.4 mg/kg. These results demonstrated that COC is the least toxic,
and NCE is the most toxic metabolites among these compounds. Therefore, an ideal
enzyme therapy should detoxify cocaine and these toxic metabolites efficiently.
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Figure 3.3 Dose-dependent lethality of norcocaethylene (NCE) and norcocaine (NC) in
male Swiss Webster mice.
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Table 3.2 LD50 of cocaine and its toxic metabolites in male Swiss Webster mice.
Compound

Cocainea

Cocaethylenea

Norcocaineb

93.0 ± 1.1

63.8 ± 1.0

49.7 ± 1.6

Norcocaethyleneb

LD50 ± SD
39.4 ± 1.0

(mg/kg)
a

Data (determined using the same strain of mice) from reference (Hearn et al. 1991)

b

This study.
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3.3.4

Accelerated cocaine metabolism by CocH5-Fc(6M) in rats co-administered with
alcohol and cocaine

To evaluate the effects of CocH5-Fc(6M) on the metabolic profiles of cocaine in
rats receiving co-administration of cocaine and alcohol, rats were i.p. administered of 1
g/kg alcohol and 60 mg/kg cocaine. At 30 min following cocaine administration, rats were
i.v. administered with either saline or 1 mg/kg CocH5-Fc(6M). According to the data
depicted in Figure 3.4, following cocaine and alcohol administration, blood cocaine
concentration was gradually increasing, and reached the peak (~ 10 M) at around 30 min.
Cocaine was metabolized to generate EME, BE, NC, CE, and NCE. In comparison to the
control group, immediately after 1 mg/kg i.v. administration of CocH5-Fc(6M) at 30 min,
cocaine blood level was rapidly decreased and reached the quantification limit within a few
minutes, suggesting that CocH5-Fc(6M) efficiently hydrolyzed cocaine. This is consistent
with our previous in vitro study (Zheng et al. 2014). In consistent with the rapid decrease
of cocaine concentration, EME blood concentration was rapidly increased after enzyme
administration, suggesting EME was the major catalytic metabolite of COC in the presence
of CocH5-Fc(6M). Moreover, in addition to cocaine, the blood levels of NC, CE, and NCE
were decreased over 10-folds, and reached quantification limits after enzyme
administration, suggesting high activity of CocH5-Fc(6M) against these compounds. In
addition, compared to the control group, BE was eliminated faster after CocH5-Fc(6M)
administration, indicating that CocH5-Fc(6M) also accelerated the elimination of BE.
Overall, these results demonstrated that CocH5-Fc(6M) was able to completely and rapidly
eliminate cocaine, NC, CE, and NCE from rat blood.
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Figure 3.4 Effects of 1 mg/kg CocH5-Fc(6M) (i.v.) on metabolic profiles of cocaine in
rats.
Rats (n = 4 for each group) were i.p. administered with 1 g/kg alcohol and 60 mg/kg
cocaine, followed by i.v. administration of 1 mg/kg CocH5-Fc(6M) or saline at 30 min
after cocaine administration. Data are shown as mean  SEM.
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3.3.5

Protection and rescue effects of CocH5-Fc(6M) in rats

We further evaluated the efficiency of CocH5-Fc(6M) under a more serious
scenario by administering 1 g/kg alcohol (i.p.) and 180 mg/kg cocaine (i.p.) to rats. As
shown in Table 3.3, rats in the control group developed convulsion and died within ~3 min
after alcohol and cocaine treatment. In comparison, in protection experiment where 1 g/kg
alcohol and 180 mg/kg cocaine were i.p. administered to rats at 1 min after 1 mg/kg i.v.
administered CocH5-Fc(6M), none of the rats developed convulsion, and none of them
died. Also shown in Figure 3.5A, COC, NC, CE, and NCE were rapidly and eliminated,
suggesting CocH5-Fc(6M) accelerated the elimination of these compounds in blood. In
addition, EME level was significantly higher than other compounds at all time points.
Time-course of CocH5-Fc(6M) plasma level was displayed in Figure 3.6. CocH5-Fc(6M)
plasma concentration was remained higher than 10 mg/L though out the study.
In the rescue experiment when 1 mg/kg CocH5-Fc(6M) was i.v. administered to
rats at the onset of convulsion after administration of 1 g/kg alcohol and 180 mg/kg cocaine,
all rats were successfully rescued and recovered quickly after CocH5-Fc(6M)
administration, as shown in Table 3.3. In consistent with the protection experiment, the
physiologically inactive metabolite EME was rapidly generated and EME level was
significantly higher than other compounds since the first time points, which explained the
quick recovery of rats. COC, NC, CE, and NCE levels were rapidly reaching quantification
limit. BE level was much lower than that of EME, suggesting that the majority of COC
was metabolized by CocH5-Fc(6M) to generate EME. These results clearly demonstrate
the efficiency of CocH5-Fc(6M) in reducing cocaine-induced toxicity when alcohol is
simultaneously administered.
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Figure 3.5 Time-dependent blood concentrations of cocaine and its metabolites in rats.
Rats (n = 5) were pretreated with 1 mg/kg CocH5-Fc(6M) (i.v.) 1 min before i.p.
administration of 180 mg/kg cocaine (A). Rats (n = 5) were first i.p. administered with 180
mg/kg cocaine. 1 mg/kg CocH5-Fc(6M) was i.v. administered after the onset of cocaineinduced convulsion (B). Blood samples were collected only after CocH5-Fc(6M)
administration. Data are shown as mean  SEM.
54

Table 3.3 Effects of CocH5-Fc(6M) on cocaine (180 mg/kg, i.p.) and alcohol (1 g/kg, i.p.)
induced convulsion and lethality in rats.
Dose

Method

Number Cocaine Alcohol Time after cocaine injection (min)d

Agent
(mg/kg) (route)
None

N.A.

a

(mg/kg) (g/kg)

Convulsion Death

20

180

1

1.87 ± 0.63

2.95 ± 0.81 N.A.

5

180

1

N.A.e

N.A.e

N.A.e

Rescuec (i.v.) 5

180

1

1.99 ± 0.68

N.A.

3.02 ± 0.39

Controla

Recovery

Protectionb

CocH5Fc(6M)

of rats

1

(i.v.)

Control experiment was performed by i.p. administration of 180 mg/kg cocaine and 1 g/kg

alcohol without any treatment
b

Protection experiment was performed by pretreatment with rats with 5 mg/kg CocH1-

HSA (i.v.) 1 min before 180 mg/kg cocaine (i.p.)
c

Rescue experiment was performed by first administration of 180 mg/kg cocaine (i.p.),

followed by 5 mg/kg CocH1-HSA (i.v.) at the onset of cocaine-induced convulsion
d

The time (starting from cocaine administration) when rats were fully recovered from

cocaine-induced convulsion (occurrence of righting reflex)
e

Not applicable (N.A.)
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Figure 3.6 Time course of CocH5-Fc(6M) concentration in rat plasma following 1 mg/kg
i.v. administration.
(A) CocH5-Fc(6M) plasma concentration in protection experiment. (B) CocH5-Fc(6M)
plasma concentration in rescue experiment. Data are shown as mean  SEM.
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3.4

Discussion and Conclusions
Combinational use of cocaine and alcohol is common (Gilmore et al. 2017). It has

been reported that combinational use of alcohol and cocaine enhanced the stimulant effects,
which may encourage cocaine users to take a large amounts of these substances, thus
leading to higher risk for greater toxicity than with either drug alone (McCance-Katz et al.
1998).
Combinational use of cocaine and alcohol is also associated with a high mortality
risk in emergency department patients (Gilmore et al. 2017). In the current study, 75% of
the tested rats developed convulsion following co-administration of 40 mg/kg (i.p.) cocaine
and 1 g/kg (i.p.) alcohol, compared to 0% convulsion in rats receiving 40 mg/kg (i.p.)
cocaine alone. Likewise, in a study to investigate the lethal effects of alcohol and cocaine,
in comparison to low lethality produced by either drug alone, co-administration of 75
mg/kg (i.p.) cocaine and 6 g/kg (i.p.) alcohol resulted in 80% lethality in male mice, and
100% lethality in female mice (Schechter et al. 1995). Together, these results indicate the
increased toxicity when cocaine is co-administered with alcohol.
The effect of alcohol on cocaine PK has been investigated. In the absence of alcohol,
cocaine is metabolized via three major pathways: 1) being hydrolyzed by BChE to generate
EME; 2) being hydrolyzed by liver carboxylesterase to generate benzoylecgonine; 3) being
demethylated by P450 to generate norcocaine (Sun et al. 2002). As shown in Figure 3.1,
in the presence of alcohol, cocaine also reacts with alcohol to generate CE and NCE (Dean
et al. 1992). In our study, we injected 60 mg/kg cocaine (i.p.) with or without 1 g/kg alcohol
(i.p.) to rats. According to our observation, cocaine was mainly metabolized to generate
BE, EME, and NC. CE and NCE were only formed in the alcohol-treated group. The time57

blood concentration profiles of COC, EME, BE, and NC were not significantly different
from those in rats receiving 60 mg/kg cocaine alone. Likewise, in a study reported by Dean
et al, no significantly different cocaine level was observed in the serum and brain samples
of rats receiving i.p. administration of 2 g/kg alcohol (30 min prior to cocaine) and 25
mg/kg cocaine, compared to rats receiving cocaine alone (Dean et al. 1992). In contrast,
Hedaya et al reported higher cocaine plasma concentration in rats co-administered with
alcohol and cocaine. In this study, rats received i.v. infusion of alcohol (28 mg/kg/min),
followed by cocaine (30 mg/kg i.p.) at two hours later. They concluded that alcohol
accelerated the absorption of cocaine, which contributed to higher cocaine plasma
concentration (Hedaya et al. 1997). Since these studies used different doses and different
injection patterns of alcohol, the experiment design may explain the controversy.
However, since we did not observe significantly different cocaine concentrations
result from co-administration of alcohol, we hypothesized that the rapid formation of CE
and NCE may at least partially contributed to the potentiated cocaine toxicity. CE shares
some pharmacological properties with cocaine, including binding to the dopamine
transporter, blocking of dopamine uptake, and increasing synaptic dopamine concentration
(Hearn et al. 1991, Iyer et al. 1995). It has been demonstrated that CE was more toxic than
cocaine (Hearn et al. 1991, Iyer et al. 1995). However, the toxicity of NCE, as well as
another toxic metabolite NC, have not been characterized before.
The present study is the first time to report the dose-dependent toxicity of NC and
NCE. We used the same strain of mice with those published before (Hearn et al. 1991) to
study the acute toxicity of norcocaine and norcocaethylene, and compared the LD50 values
obtained from the dose-dependent toxicity data with those published for cocaine and CE
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(Hearn et al. 1991). According to our observation, the toxicity of COC < CE < NC < NCE,
suggesting that CE and NCE might at least partially contribute to the alcohol-potentiated
cocaine toxicity. Further, according to our preliminary experiments, while COC and CE
induced locomotor activity in animals, NCE did not display such effects (data not shown),
suggesting that the primary target for NCE is likely different from those of cocaine and CE.
This insight might make it more complicated for the development of a therapeutic agent to
treat cocaine toxicity. Further therapeutic development of cocaine toxicity treatment should
also account for detoxification of these toxic metabolites. An ideal enzyme therapy should
be capable of degrading not only cocaine itself, but also NC, CE and NCE.
In our previous studies, both CocH1 (the A199S/S287G/A328W/Y332G mutant of
human BChE) and CocH3 (A199S/F227A/S287G/A328W/Y332G mutant of human BChE)
showed significantly improved in vitro and in vivo activities in hydrolyzing COC, NC, CE,
and BE, compared to wild-type BChE (Pan et al. 2005, Hou et al. 2014, Zhan et al. 2014,
Chen et al. 2016). CocH5 (the A199S/F227A/P285A/S287G/A328W/Y332G mutant of
human BChE) is the most efficient cocaine-metabolizing enzyme reported so far (Zheng et
al. 2014). In fact, based on our in vitro data (unpublished), CocH5 displayed further
enhanced catalytic activities against COC, NC, CE, and NCE, compared to CocH1 and
CocH3. In the present study, CocH5 was fused to a six-mutated Fc domain of IgG1 to yield
a long-acting enzyme entity. This is the first time that CocH5-Fc(6M) is investigated for
the in vivo efficacy in treating cocaine overdose.
In the present in vivo studies, compared to the control group, 1 mg/kg i.v.
administered CocH5-Fc(6M) accelerated the elimination of COC, BE, NC, CE, and NCE
effectively in rats, suggesting the improved catalytic efficiency of CocH5-Fc(6M) in
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hydrolyzing not only cocaine, but also these toxic metabolites. In addition, CocH5-Fc(6M)
shifted the metabolic clearance of cocaine, favoring the formation of EME. Therefore,
EME was rapidly generated in rats after CocH5-Fc(6M) administration.
In further protection and rescue experiments, 1 mg/kg (i.v.) CocH5-Fc(6M)
successfully protected and rescued rats from 180 mg/kg (i.p.) cocaine and 1 g/kg (i.p.)
alcohol. Without CocH5-Fc(6M) treatment, all the rats died quickly after cocaine and
alcohol administration. However, none of the rats developed toxic signs in the protection
experiment, and all the rats recovered quickly after enzyme administration in the rescue
experiment. The blood levels of COC, BE, NC, CE, NCE were considerably lower than
EME level since the first time points. In conclusion, these results demonstrated the
effectiveness and therapeutic potential of CocH5-Fc(6M) in reducing cocaine toxicity,
especially when alcohol is co-administered.
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CHAPTER 4. DEVELOPMENT OF A MATHEMATICAL MODEL TO PREDICT THE
EFFECTS OF COCAINE HYDROLASE ON COCAINE PHARMACOKINETICS
IN RAT BLOOD AND BRAIN
4.1

Introduction
Cocaine addiction is a chronic brain disease characterized by loss of control over

drug use, or compulsive drug seeking and drug taking despite adverse consequences
(Nestler 2001, Everitt et al. 2005). Blockage of dopamine transporter (DAT) is believed to
be the major mechanism of cocaine addiction (Ritz et al. 1987). DAT is responsible for
regulating synaptic dopamine level by recycling dopamine back to the pre-synaptic neuron
(Kalivas 2007). Cocaine binds to DAT and blocks the reuptake of dopamine, resulting in
elevated dopamine level in synaptic cleft. Increased dopamine overstimulates dopamine
receptor, leading to a cascade of events, such as producing euphoria-like feelings (Volkow
et al. 1997). Repeated cocaine intake and chronic exposure to cocaine may result in
neuroadaptations, including DA hypoactivity, which contributes to craving and hedonic
dysregulation in addictive patients (Dackis et al. 2005).
Despite the demand for treatment, there is no U.S. Food and Drug Administration
(FDA) approved pharmacotherapy specific for cocaine addiction (Chan et al. 2018).
Conventional pharmacodynamic anti-cocaine treatment approach uses a small-molecule
drug to antagonize cocaine-induced effects at the sites of action. However, it is difficult to
block cocaine-induced effects without affecting the normal functions of the central nervous
system (CNS) (Gorelick 2012, Zheng et al. 2012). Therefore, this approach has not yet
been proven effective.
An alternative approach uses therapeutic proteins to keep cocaine concentration
below the minimal effective concentration, by neutralizing cocaine or accelerating cocaine
61

metabolism (Gorelick 2012, Zheng et al. 2012). As therapeutic proteins are too large to
pass through blood brain barrier, this approach should have no direct effect on the CNS
(Gorelick 2012, Zheng et al. 2012). Examples of this approach include monoclonal anticocaine antibodies (mAbs), anti-cocaine vaccines, and cocaine-metabolizing enzymes.
Unlike the stoichiometric binding of antibody molecule to cocaine, one enzyme molecule
can degrade multiple cocaine molecules, depending on the turnover number (kcat) and
Michaelis-Menten constant (KM) (Zheng et al. 2012). Thus, cocaine-metabolizing enzymes
are expected to be more promising for anti-cocaine treatment than antibodies.
Butyrylcholinesterase (BChE) is an endogenous enzyme that hydrolyzes cocaine to
generate biologically inactive metabolites (Murthy et al. 2015). Unfortunately, the
therapeutic use of wild-type BChE is limited due to its low activity against the naturally
occurring cocaine (kcat = 4.1 min-1 and KM = 4.5 M) (Sun et al. 2002). Through structureand mechanism-based computational modeling and simulation, a series of BChE mutants
have been developed with at least 1000-fold improved catalytic activity against (-)-cocaine.
For example, compared to wild-type BChE, CocH1 (the A199S/S287G/A328W/Y332G
mutant of human BChE) and CocH3 (the A199S/F227A/P285A/S287G/A328W/Y332G
mutant of human BChE), have significantly improved activities against not only cocaine,
but also its toxic metabolites norcocaine, cocaethylene, and benzoylecgonine (Pan et al.
2005, Zheng et al. 2008, Xue et al. 2013, Hou et al. 2014, Zhan et al. 2014, Chen et al.
2016). These BChE mutants were recognized as “true cocaine hydrolases” (CocHs)
(Brimijoin et al. 2008). In addition, an albumin-fused CocH1, also known as TV-1380, was
investigated in clinical trials by Teva Pharmaceutical Industries as a treatment for cocaine
addiction. The clinical trials indicated the anti-cocaine effects of TV-1380 in human
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(Gilgun-Sherki et al. 2016). Further, by using a two-step computational design approach,
CocH5 (the A199S/F227A/P285A/S287G/A328W/Y332G mutant of human BChE) has
been reported. CocH5 has an extremely high catalytic efficiency (kcat/KM = ~4.0 x 109 min1

M-1) against cocaine (Zheng et al. 2014). Therefore, we expect CocH5 to be the most

promising enzyme entity for anti-cocaine treatment.
Cocaine addiction treatment requires long-term intervention. Therefore, in addition
to high catalytic efficiency, an ideal cocaine-metabolizing enzyme for the treatment of
cocaine addiction should have a long biological half-life (Gorelick 2012). In our previous
studies, a triple-mutated (A1V/D142E/L144M) Fc domain of IgG1 was fused to the Cterminus of CocH3. This long-acting form of CocH3 displayed a half-life ~107 h in rats,
and it accelerated cocaine metabolism in rats for at least 20 days (Chen et al. 2016).
Recently, CocHs fused with six-mutated Fc (i.e. 6M) were successfully designed in our
lab. Compared to CocH-Fc(3M), CocH-Fc(6M) exhibited a further prolonged half-life in
rats. Therefore, we expect Fc(6M)-fused CocH5 to be more promising in treating cocaine
addiction.
It is costly and time-consuming to investigate the long-term efficacy of a CocH in
animal addiction models, which requires a large amount of purified enzyme and human
effort. Alternatively, a mathematical model could predict cocaine levels in rats
administered with CocHs, without the need for further experimental data, thus saving time
and expense. Once established, such model can be used to predict doses at which efficacy
can be expected, or predict efficacy at a given dose (Choo et al. 2013).
In the present study, we aim to: 1) evaluate the effects of CocH5-Fc(6M) on the
elimination of cocaine and its toxic metabolites in rat blood and brain; 2) develop a

63

mathematical model to predict the effects of CocH5-Fc(6M) on altering the metabolic
profiles of cocaine in rat blood and brain. For these purposes, we measured cocaine and its
metabolites levels in blood and brain samples of rats receiving CocH5-Fc(6M), and
demonstrated that CocH5-Fc(6M) effectively accelerated the hydrolysis of cocaine and its
toxic metabolites in both rat blood and brain. A two-compartment model was developed to
characterize the PK profiles of CocH5-Fc(6M) in rats. Next, CocH5-Fc(6M) PK model
was incorporated to a PD model to predict the effects of CocH5-Fc(6M) on cocaine. This
combined PK-PD model was fitted to three datasets simultaneously, and it described the
experimental data well. Overall, this study clearly demonstrated the therapeutic potential
of CocH5-Fc(6M) for cocaine addiction treatment. We expect this PK-PD model could
facilitate further preclinical and clinical studies.
4.2

Materials and Methods

4.2.1

Materials

CocH5 (the A199S/F227A/P285A/S287G/A328W/Y332G mutant of human BChE)
was truncated after amino acid 529, and was fused with six-mutated Fc region of human
IgG1. The protein was expressed by lentivirus-transfected CHO-S cells, and was purified
by using protein A affinity chromatography on an ÄKTA Avant 150 system (GE
Healthcare Life Sciences, Pittsburgh, PA). Purified CocH5-Fc(6M) was stored in buffer
(50 mM HEPES, 20% sorbitol, 1 M glycine, pH 7.4) at − 80 °C before use.
Cocaine, EME, benzoylecgonine, and norcocaine were provided by the National
Institute on Drug Abuse (NIDA) Drug Supply Program (Bethesda, MD). Deuterated
cocaine, EME, benzoylecgonine were purchased from Cerilliant (Round Rock, TX). [3H]64

(-)-cocaine (50 Ci/mmol) was purchased from PerkinElmer (Waltham, MA). Protein A was
ordered from ProMetic (Rockville, MD). All other chemicals were purchased from Thermo
Fisher Scientific (Waltham, MA) or Sigma-Aldrich (St. Louis, MO).
4.2.2

Animals

Male Sprague-Dawley rats (~ 350 g) were ordered from Harlan (Harlan,
Indianapolis, IN), and housed initially as one or two rats per cage. All rats were kept at
room temperature of 21–22°C, allowing ad libitum access to food and water. Animal
housing areas were maintained on a 12 h light/12 h dark cycle, with lights on at 8:00 a.m.
Experiments were performed in accordance with the Guide for the Care and Use of
Laboratory Animals as adopted and promulgated by the National Institutes of Health. The
animal protocol was approved by the IACUC (Institutional Animal Care and Use
Committee) at the University of Kentucky.
4.2.3

Blood sample collection and analysis

To measure enzyme plasma concentration, blood samples (75 l) were collected
from saphenous vein using heparin-treated capillary tubes at various time-points after
enzyme administration. Collected blood samples were centrifuged for 15 min at a speed of
5000 g, and separated plasma was kept at 4°C before analysis. A sensitive radiometric
assay as described before (Brimijoin et al. 2002) was performed to measure enzyme
concentration in plasma. Briefly, 10 l of plasma sample was mixed with 140 l of 0.1 M
phosphate buffer (pH = 7.4). 50 l of 400 M [3H]-(-)-cocaine was added to the mixture
to initiate enzymatic reaction. The reaction proceeded at room temperature, and was
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stopped by adding 200 l of 0.1 M hydrochloric acid. The radioactive product benzoic acid
was extracted by toluene for scintillation counting. The enzyme concentration ([E]) was
calculated based on the equation: [E] = Vmax/kcat, where Vmax is the maximum rate the
enzymatic reaction can achieve, kcat is the turnover number of the enzyme. Enzyme kinetic
parameters were obtained from our previous study (Zheng et al. 2014).
To determine concentrations of cocaine and its metabolites in whole blood, rat
blood samples (75 l) were collected from saphenous vein using heparin-treated capillary
tubes at various time-points after cocaine administration, and were mixed immediately with
100 µL of 0.1% formic acid containing 250 µM paraoxon. Blood samples were stored at 80 °C before use. For analysis, thawed blood sample was mixed with 500 µl of 4% formic
acid and 75 µL of 100 nM internal standards. The mixture was then subject to a one-step
solid-phase extraction (SPE) using mixed cation exchange model solid phase extraction
cartridges (Oasis MCX 1 cc Vac Cartridge, 10 mg) purchased from Waters (Milford, MA).
Briefly, the loaded sample was washed twice with 1 mL methanol, followed by elution
using 1 mL methanol/7.5% ammonium hydroxide (95:5, v/v).
To determine the concentrations of cocaine and its metabolites in brain, rat brain
samples were quickly removed at different time points after cocaine administration.
Surface blood was blotted away, and brain samples were weighed and immediately frozen
in 1% trichloroacetic acid (TCA) containing 250 µM paraoxon on dry ice. The brain
samples were stored at -80 °C before use. For analysis, thawed rat brain samples were
homogenized in cold 1% TCA containing 250 µM paraoxon (5 mL of homogenizing
solution per gram of brain sample) using a VWR homogenizer with VWR 7 x 95 mm
Saw-Tooth Generator Probe (VWR International LLC, Radnor, PA). The homogenate was
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then centrifuged at 13,000 rpm at 4 °C for 20 min. 200 µL of supernatant was collected
and mixed with 50 µL of 50 ng/mL internal standards. The mixture was then extracted by
750 µL of hexane. Resulting inorganic phase was collected and mixed with 750 µL of 1%
TCA. The mixture was then subject to solid phase extraction as described above.
A quantitative LC-MS/MS assay described in our previous study (Chen et al. 2017)
was applied to quantify cocaine and its metabolites in whole blood and brain samples.
Briefly, extracted samples were evaporated and re-suspended in 0.1% formic acid before
loading to a Shimadzu HPLC system (Shimadzu, Kyoto, Japan), consisting of a DGU20A/3R degasser, LC-20 AD binary pumps, CBM-20A controller, and SIL-20A/HT auto
sampler. Mobile phase A consisted of 0.1% formic acid and mobile phase B consisted of
0.1% formic acid: acetonitrile (10:90, v/v). Samples were loaded to an Atlantis T3 (100 Å,
3 μm, 2.1 mm X 150 mm I.D) column (Waters, Milford, MA) and were eluted by gradient.
AB SCIEX tripleTOF™ 5600 (AB SCIEX, Redwood City, CA) was applied in positive
ion and high sensitivity mode for analysis.
4.2.4

Experimental design

Determination of pharmacokinetic profiles of CocH5-Fc(6M) in rats

Rats were i.v. administered with purified CocH5-Fc(6M) via tail vein at different
doses. Blood samples were collected at different time points after enzyme administration.
Plasma concentrations were determined as described above. Time-dependent plasma
concentrations of enzyme under two dose levels were simultaneously fitted using a twocompartment model, assuming linear elimination from central compartment. The CocH5-
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Fc(6M) PK model was fitted using Monolix (Lixoft, Batiment D, Antony, France). Model
structure was displayed in Figure 4.1.
CocH5-Fc(6M) PK Model equations
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and A2

represent the amount of CocH5-Fc(6M) in central and

peripheral compartments, respectively. Cenzyme represents CocH5-Fc(6M) concentration
in central compartment. Initial condition for equation (1) is the dose of the enzyme, and for
equation (2) is 0.

68

Figure 4.1 Schematic representation of the PK model used to describe CocH5-Fc(6M) in
rats.
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Characterization of the effects of CocH5-Fc(6M) on cocaine metabolic profiles in rats

Rats (n = 3) were i.v. administered with saline or 0.3 mg/kg CocH5-Fc(6M) via tail
vein, followed by an i.p. administration of cocaine (5 mg/kg or 20 mg/kg). Rats were decapitalized at different time points after cocaine administration. Brain and trunk blood
samples were collected and analyzed as described above.
PK-PD model development

Pharmacodynamic effects of CocH5-Fc(6M) can be described by the metabolic
profiles of cocaine and its metabolites in the presence of the enzyme. Therefore, a PK-PD
model, which in fact is a “double-PK model”, was developed in this study to evaluate the
effects of CocH5-Fc(6M). Figure 4.2 describes the model structure to characterize the
concentrations of cocaine and its metabolites in rat blood and brain. The model includes
one central compartment and one brain compartment for each compound, since two
compartments were adequate to characterize the kinetic profiles of each compound. In the
absence of CocH5-Fc(6M), cocaine (COC) is mainly metabolized to generate ecgonine
methyl ester (EME), benzoylecgonine (BE), and norcocaine (NC). While in the presence
of CocH5-Fc(6M), the enzyme accelerates the hydrolysis of COC, BE, and NC
independently. CocH5-Fc(6M) was assumed to accelerate elimination of cocaine,
norcocaine, and benzoylecgonine only in the central compartment.
In this model, NC is only formed from the pre-systemic depot, since we did not
observe NC formation following i.v. administration of cocaine in our previous experiments.
In addition, in our previous studies, we found that AUC ratio of BE to EME was larger
following i.p. administration of cocaine than that following i.v. administration of cocaine,
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suggesting BE was formed both pre-systemically and in central compartment. These
assumptions are consistent with previously reported study that norcocaine was only formed
during first-pass effect, while benzoylecgonine was formed systemically and presystemically following p.o. administration of cocaine (Sun et al. 2001). In addition, two
transit compartments were included to characterize the delayed absorption of BE. Basal
elimination of EME, BE, NC were assumed only occurred in central compartment. Since
cocaine was extensively metabolized, renal excretion of cocaine was not described in this
model. We used first-order rate constants to describe the endogenous formation of EME
and BE from COC, instead of using Michaelis-Menten kinetics, as cocaine displayed linear
pharmacokinetic profiles within the dose range we studied.
Observed data from three experiments were simultaneously fitted using the PK-PD
model, as described in Table 4.1. Briefly, in the first and second experiments, rats were
only administered with 20 mg/kg (i.p.) cocaine, and 5 mg/kg (i.p.) cocaine, respectively.
In the third experiment, rats were administered with 0.3 mg/kg CocH5-Fc(6M) (i.v.) and
20 mg/kg cocaine (i.p.). The above-mentioned PK-PD model was simultaneously fitted to
the experimental data using Monolix (Lixoft, Batiment D, Antony, France), by fixing
CocH5-Fc(6M) concentration to 0 for control groups, or by incorporating CocH5-Fc(6M)
PK model for treatment group. Model species were summarized in Table 4.2.
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Figure 4.2 Schematic representation of PK-PD model.
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Table 4.1 Datasets used to simultaneously fit to PK-PD model.
Dataset 1

Dataset 2

Dataset 3

Dose of CocH5-Fc(6M) (route)

N.A.

N.A.

0.3 mg/kg (i.v.)

Dose of cocaine (route)

20 mg/kg (i.p.)

5 mg/kg (i.p.)

20 mg/kg (i.p.)

73

Table 4.2 PK-PD model species
Species

Definition

Unit

XDose

Injected cocaine in pre-systemic depot

mole

CcCOC

COC concentration in central compartment

M

CbCOC

COC concentration in brain compartment

M

CcEME

EME concentration in central compartment

M

CbEME

EME concentration in brain compartment

M

CcBE

BE concentration in central compartment

M

CbBE

BE concentration in brain compartment

M

CcNC

NC concentration in central compartment

M

CbNC

NC concentration in brain compartment

M

Cenzyme

CocH5-Fc(6M) concentration in plasma

M
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PK-PD model equations
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where initial condition for equation (4) is the dose of cocaine, and for (5) to (14) is 0.
4.2.5

Sensitivity analysis

To determine the relative impact of selected parameter on the output of the model,
a sensitivity analysis was performed. Brain cocaine AUC was selected as the output, as this
reflects the exposure of cocaine in brain. Enzyme concentration was fixed to 0.01 M in
sensitivity analysis. Selected parameter was increased or decreased by 50%, and the
resultant brain cocaine AUC values were compared.
4.3

Results

4.3.1

Pharmacokinetic profiles of CocH5-Fc(6M) in rats

Rats were i.v. administered with CocH5-Fc(6M) at 3 mg/kg or 0.075 mg/kg. As
shown in Figure 4.3, under both dose conditions, plasma concentration of CocH5-Fc(6M)
declined bi-exponentially in rats. A two-compartment model with linear elimination from
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central compartment was adequate to characterize the PK profile of CocH5-Fc(6M). As
shown in Table 4.3, the parameters were estimated with accuracy. In addition, the same
set of parameters were able to describe the parallel decline of CocH5-Fc(6M) plasma level
among the two dose levels, suggesting linear pharmacokinetics of CocH5-Fc(6M) in rats,
with little effect of target-mediated drug disposition (TMDD) in rats.
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CocH4-Fc(6M) Plasma Concentration (µM)

Observation (3 mg/kg)
Observation (0.075 mg/kg)
Prediction (3 mg/kg)
Prediction (0.075 mg/kg)

1
0.1
0.01
0.001
0.0001
0

20

40

60

Time (h)

Figure 4.3 Time-dependent plasma concentration profiles of CocH5-Fc(6M) in rats.
Rats (n = 4 for each dose) received i.v. administration of 3 mg/kg or 0.075 mg/kg CocH5Fc(6M). Observed data are shown as Mean  SEM.
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Table 4.3 Estimated parameters obtained by fitting the CocH5-Fc(6M) PK model to the
observed data.
Parameter Definition (unit)

Estimate (CV%)

𝑒𝑛𝑧𝑦𝑚𝑒

Enzyme volume of central compartment (L)

0.0177 (7.86%)

𝑒𝑛𝑧𝑦𝑚𝑒

First-order elimination rate constant of enzyme (1/day)

0.187 (6.23%)

𝑒𝑛𝑧𝑦𝑚𝑒

Intercompartment rate constant (1/day)

0.378 (4.55%)

Intercompartment rate constant (1/day)

0.42 (6.58%)

𝑉𝑐

𝐾10
𝐾12

𝑒𝑛𝑧𝑦𝑚𝑒

𝐾21
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4.3.2

Effect of CocH5-Fc(6M) on the metabolic profiles of cocaine in rat blood and brain

Rats were i.v. administered with saline or 0.3 mg/kg CocH5-Fc(6M) via tail vein,
followed by an i.p. administration of 20 mg/kg or 5 mg/kg cocaine. As shown in Figure
4.4 and Figure 4.5, in both control groups, cocaine (COC) and norcocaine (NC) rapidly
entered brain, and declined in parallel with the corresponding compounds in blood. Brain
concentrations (corrected by excluding corresponding compound in residual blood, and
assuming tissue density is 1 g/mL) of these two compounds were higher than the
corresponding blood concentrations at all time points. In comparison, ecgonine methyl
ester (EME) entered brain much slowly. EME brain concentration was gradually increased
and became higher than the corresponding blood concentration after ~60 minutes. In
comparison, benzoylecgonine (BE), as a zwitterion, was very difficult to penetrate to brain.
Therefore, BE brain concentration was lower than the blood concentrations at all time
points. This is consistent with previously reported observation that BE concentration in
brain was significantly lower than that in blood (Misra et al. 1975).
In comparison, as shown in Figure 4.6, in rats receiving 0.3 mg/kg (i.v.) CocH5Fc(6M) and 20 mg/kg (i.p.) cocaine, COC and NC in blood and brain were rapidly
eliminated by CocH5-Fc(6M). Both blood and brain levels for COC and NC were
approaching the quantification limits. In consistent with the fast elimination of COC, blood
and brain concentrations of EME were rapidly increased. In addition, compared to the 20
mg/kg control group, BE blood and brain levels were also considerably lower and
eliminated faster, suggesting CocH5-Fc(6M) accelerates the elimination of BE.
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Figure 4.4 Simultaneous PK-PD model fitting of the observed concentration-time profiles
in rats following 20 mg/kg (i.p.) cocaine.
Dashed lines represent the quantification limits.
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Figure 4.5 Simultaneous PK-PD model fitting of the observed concentration-time profiles
in rats following 5 mg/kg (i.p.) cocaine.
Dashed lines represent the quantification limits.

82

EME

1000000

1000000

100000

100000

Concentration (nM)

Concentration (nM)

Blood Concentration (observation)
Brain Concentration (observation)
Blood Concentration (prediction)
Brain Concentration (prediction)
Cocaine

10000
1000
100
10
1

10000
1000
100
10
1

0.1

0.1
0

30

60

90 120 150 180 210 240
Time (min)

0

30

60

NC

1000000

1000000

100000

100000

Concentration (nM)

Concentration (nM)

BE

10000
1000
100
10
1

90 120 150 180 210 240
Time (min)

0.1

10000
1000
100
10
1
0.1

0

30

60

90 120 150 180 210 240
Time (min)

0

30

60

90 120 150 180 210 240
Time (min)

Figure 4.6 Simultaneous PK-PD model fitting of the observed concentration-time profiles
in rats following 0.3 mg/kg (i.v.) CocH5-Fc(6M) and 20 mg/kg (i.p.) cocaine.
Dashed lines represent the quantification limits.
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4.3.3

PK-PD model fitting

The PK-PD model described above were simultaneously fitted to three
experimental datasets, which included the concentrations of four compounds in both blood
and brain. As summarized in Table 4.4, the model parameters were estimated with good
confidence. The model was able to simultaneously capture the time-dependent
concentration profiles of cocaine and its three metabolites in rat blood and brain. In addition,
the model reasonably predicted the effects of CocH5-Fc(6M) on these compounds. The
model predicted that CocH5-Fc(6M) accelerated the elimination of COC, BE, and NC in
both rat blood and brain. In comparison, EME was generated faster in the presence of
CocH5-Fc(6M). This model also indicates that the higher the enzyme concentration, the
faster the elimination of COC, BE, and NC, and the faster the generation of EME. Overall,
there was good agreement between the model-predicted and observed data.

84

Table 4.4 Parameter estimates obtained by simultaneous fitting PK-PD model to the
experimental data.
Parameter

Definition (unit)

Estimate (CV%)

𝐹𝐾𝑎𝐶𝑂𝐶

First-order absorption rate constant of COC (1/min)

0.291 (3.21%)

𝐹𝐾𝑎𝐵𝐸

First-order absorption rate constant of BE (1/min)

0.133 (13.3%)

𝐹𝐾𝑎𝑁𝐶

First-order absorption rate constant of NC (1/min)

0.0307 (12.1%)

Formation rate constant of BE (1/min)

0.0393 (8.79%)

𝐾𝑓𝐸𝑀𝐸

Formation rate constant of EME (1/min)

0.0036 (10.3%)

𝐶𝑂𝐶
𝐾12

Intercompartment rate constant of COC (1/min)

0.00704 (9.07%)

𝐶𝑂𝐶
𝐾21

Intercompartment rate constant of COC (1/min)

0.225 (9.76%)

𝐸𝑀𝐸
𝐾12

Intercompartment rate constant of EME (1/min)

0.000803 (3.61%)

𝐸𝑀𝐸
𝐾21

Intercompartment rate constant of EME (1/min)

0.0155 (4.19%)

𝐸𝑀𝐸
𝐾10

First-order elimination rate constant of EME (1/min)

0.0127 (7.34%)

𝐵𝐸
𝐾12

Intercompartment rate constant of BE (1/min)

2.72E-05 (14.7%)

𝐵𝐸
𝐾21

Intercompartment rate constant of BE (1/min)

0.0269 (18.7%)

𝐵𝐸
𝐾10

First-order elimination rate of BE (1/min)

0.0102 (11.7%)

𝑁𝐶
𝐾12

Intercompartment rate constant of NC (1/min)

0.00675 (14.0%)

𝑁𝐶
𝐾21

Intercompartment rate constant of NC (1/min)

0.249 (18.4%)

𝑁𝐶
𝐾10

First-order elimination rate constant of NC (1/min)

0.06 (7.75%)

Physiological volume of rat brain (mL)

1.8 (Fixeda)

𝑉𝑐𝐶𝑂𝐶

Volume of central compartment of COC (mL)

620 (Fixedb)

𝑉𝑐𝐸𝑀𝐸

Volume of central compartment of EME (mL)

168 (6.56%)

𝑉𝑐𝐵𝐸

Volume of central compartment of BE (mL)

113 (Fixedb)

𝑉𝑐𝑁𝐶

Volume of central compartment of NC (mL)

763 (Fixedb)

𝐾𝑓𝐵𝐸

𝑉𝑏
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Table 4.4 (continued)
𝐷𝑜𝑠𝑒
𝐾10

First-order elimination rate constant of dose (1/min)

3.28 (3.18%)

𝑒𝑓𝑓

In vivo turnover number of CocH5 against COC (1/min)

217 (21.3%)

𝑘𝑐𝑎𝑡,𝐵𝐸

𝑒𝑓𝑓

In vivo turnover number of CocH5 against BE (1/min)

8.27 (18.1%)

𝑒𝑓𝑓

In vivo turnover number of CocH5 against NC (1/min)

77.6 (47.5%)

𝐵𝐸
𝐾𝑇𝐶

Rate constant describing delayed absorption of BE (1/min)

0.318 (9.53%)

𝐶𝑂𝐶
𝐾𝑀

Michaelis-Menten constant of CocH5 against COC (M)

3.6 (Fixedc)

𝐵𝐸
𝐾𝑀

Michaelis-Menten constant of CocH5 against BE (M)

207 (Fixedd)

𝑁𝐶
𝐾𝑀

Michaelis-Menten constant of CocH5 against NC (M)

7.6 (Fixede)

𝑘𝑐𝑎𝑡,𝐶𝑂𝐶

𝑘𝑐𝑎𝑡,𝑁𝐶

a

Physiological value from reference (Boxenbaum 1982).

b

c

Data from reference (Mets et al. 1999).

Data from reference (Zheng et al. 2014).

d

Data from reference (Chen et al. 2016).

e

Unpublished data.
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4.3.4

Sensitivity analysis

A sensitivity analysis was performed to evaluate the key determining factors for the
AUC of brain cocaine. According to Figure 4.7, among the selected parameters, the PKCOC
COC
Dose eff
enzyme
PD model was sensitive to FK COC
. This result
a , K12 , K 21 , K10 , 𝑘cat,COC , and C

indicates that the exposure of cocaine in rat brain was largely dependent on the absorption
rate of cocaine, the intercompartmental rate constants of cocaine between blood and brain,
the rate constant of injected cocaine being lost pre-systemically, the catalytic activity of
CocH5-Fc(6M) , and the concentration of CocH5-Fc(6M).
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% Change in Brain Cocaine AUC

Sensitivity Analysis
Increase parameters
Decrease parameters

150
100
50
0
-50
-100
-150

e
C
C zym
CO
O n
1 ff at,C e
2
C
K e c

K

e
os
D
0
K1

C
CO
2
K1

F

C
CO
Ka

BE
Kf

E
EM
Kf

F

BE
Ka

F

NC
Ka

Figure 4.7 Sensitivity analysis demonstrating the effects of increasing and decreasing
selected parameter value by 50% on brain cocaine AUC.
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4.4

Discussion and Conclusions
Compared to acute cocaine toxicity treatment that requires a very fast onset, cocaine

addiction treatment requires a long-acting intervention (Woods et al. 2016). Chronic
exposure to cocaine leads to neuroadaptation of dopamine system, which could be
maintained for a long time. Although possible, the normalization of dopaminergic function
is an extremely slow process (Zheng et al. 2012). In monkeys that administered with
cocaine for 100 days, up-regulation of dopamine transporter (DAT) in dorsal and ventral
striatum, decreased dopamine (DA) D2 receptors, and increased DA D1 receptors were
still observed after 30 days of abstinence. In the same study, it took 90 days of abstinence
for the DAT and DA receptors back to the normal levels in monkeys (Beveridge et al.
2009). Therefore, it is critical to protect cocaine-addicted patients from further damage to
the DA system, while allowing the DA system to be back to normal. This requires a
therapeutic agent to effectively antagonize the effects of cocaine, and also maintain a longacting effect in the long-term treatment process.
Our previously designed CocH1 and CocH3 have significantly improved catalytic
activities against cocaine, norcocaine, cocaethylene, and benzoylecognine (Pan et al. 2005,
Zheng et al. 2008, Xue et al. 2013, Hou et al. 2014, Zhan et al. 2014, Chen et al. 2016). In
animal behavioral studies, a constantly high level of CocH3 (~18.4 U/ml in plasma)
delivered by adenoviral vector was able to prevent reinstatement of cocaine-seeking
behavior in rats for at least six months (Anker et al. 2012). Compared to CocH1 and CocH3,
CocH5 has further enhanced in vitro activity against cocaine (Zheng et al. 2014). Thus we
expect that CocH5 to be more efficient in cocaine addiction treatment. In fact, based on
our observation in current study, a single dose (0.3 mg/kg, i.v.) of CocH5-Fc(6M)
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accelerated the elimination of cocaine, norcocaine, and benzoylecgonine in both rat blood
and brain. Both blood and brain levels of cocaine and these active metabolites were
considerably lower than those in the corresponding control group, demonstrating the
efficiency of CocH5-Fc(6M) in antagonizing the effects induced by these active
compounds.
In addition, it has been widely explored to extend the half-life of therapeutic protein
by fusing it with the Fc domain of human IgG1. Fc binds to neonatal Fc receptor (FcRn) at
pH 6.0-6.5, but weakly at pH 7.0-7.5 (Raghavan et al. 1995). Therefore, by binding to Fc
at a low pH in endosome, FcRn protects the protein from further delivery and degradation
in the lysosome (Suzuki et al. 2010). This mechanism can explain the long half-life of IgG1
in human (Morell et al. 1970). In the current study, CocH5 was fused with six-mutated Fc
to generate CocH5-Fc(6M). According to our observation, CocH5-Fc(6M) exhibited an
elimination half-life of ~9 days in rats. This long-acting CocH5-Fc(6M) would require
lower doses and less dosing frequency for administration in the long-term therapy.
In the present study, linear pharmacokinetics of CocH5-Fc(6M) was observed in
rats within the dose range we studied, showing little effect of target-mediated drug
disposition. Based on this observation, we developed a two-compartment model with linear
elimination from central compartment to characterize the PK profile of CocH5-Fc(6M).
The PK model described the observed data well. In addition, the PK model-estimated
central volume of distribution was 17.7 mL, which was only slightly higher than the
reported physiological volume (~9.06 mL) of rat plasma (Shah et al. 2012), suggesting
CocH5-Fc(6M) was mainly distributed in the systemic circulation.
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To predict the pharmacodynamic effects of CocH5-Fc(6M) on cocaine and its
metabolites, the CocH5-Fc(6M) PK model was incorporated to build a PK-PD model. Only
two compartments (central and brain) were used for each compound in this model, as they
were adequate to capture the observed data. Since we did not observe non-linear behaviors,
first-order rate constants were used to describe the absorption, distribution, endogenous
metabolism, and excretion processes of all four compounds. This PK-PD model was thus
simultaneously fitted to cocaine, EME, benzoylecgonine, and norcocaine blood and brain
concentrations in rats in three different groups. Generally, the model prediction agreed with
the observation. In the absence of CocH5-Fc(6M), cocaine and norcocaine entered the
brain rapidly, and remained at high levels in the brain. In contrast, EME and BE slowly
entered the brain. The difference in hydrophilicity of these compounds may explain the
different distributions of these compounds in brain. However, when 0.3 mg/kg (i.v.)
CocH5-Fc(6M) and 20 mg/kg (i.p.) cocaine were administered to the rats, the enzyme
accelerated the elimination of COC, NC, and BE in blood, which also leads to faster
elimination of these compounds in brain. The rapidly eliminated cocaine was converted to
EME by the enzyme. Based on our preliminary experiments, 5 mg/kg i.p. injected cocaine,
which produces ~3 M cocaine in rat brain, did not cause locomotion activity in rats. In
comparison, 0.3 mg/kg (i.v.) CocH5-Fc(6M) reduced cocaine brain concentration to ~300
nM, suggesting that CocH5-Fc(6M) at this dose can block the stimulant effects induced by
20 mg/kg (i.p.) cocaine. This model also predicts that, higher CocH5-Fc(6M) level leads
to faster elimination of COC, NC, and BE, and faster formation of EME. In addition, by
performing sensitivity analysis, this model also predicts that cocaine brain AUC was most
COC
COC
Dose eff
enzyme
affected by FK COC
. This implies that, despite
a , K12 , K 21 , K10 , k cat,COC , and C
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the properties that investigators could not control, one could expect to minimize cocaine
exposure in brain by increasing the catalytic activity of cocaine hydrolase, or by increasing
CocH5-Fc(6M) level in blood.
With large molecular weight (~110 kDa), CocH5-Fc(6M) is not expected to cross
blood-brain barrier (BBB). In comparison, cocaine enters brain rapidly, and binds to its
targets in brain with binding affinities less than 1 M (Raje et al. 2003). As such, CocH5Fc(6M) is believed to exert its effects by accelerating the metabolism of cocaine in the
blood, creating the concentration gradients between blood and brain, so that cocaine in the
brain transports back to the blood to offset the loss in the blood. Therefore, cocaine blood
concentration may not reflect its brain concentration. In fact, considering the high binding
affinities of cocaine to its targets in brain (Raje et al. 2003), it is not surprising to find a
large amount of cocaine bound in brain. In the present study, we observed ~6.5-fold higher
cocaine concentration in rat brain than that in blood. Likewise, Benuck et al reported that
cocaine concentration in brain was seven-fold higher than in plasma of mice receiving 25
mg/kg i.p. injected cocaine (Benuck et al. 1987). In a study that investigates the effects of
humanized anti-cocaine monoclonal antibody on the distribution of cocaine, the AUC for
brain cocaine in rats was ~four-fold higher than that for plasma cocaine (Norman et al.
2014). In contrast, some researchers reported smaller brain/blood concentration ratio from
samples obtained by microdialysis (Pan et al. 1991). This may result from the fact that,
instead of measuring the concentration of total cocaine (bound plus unbound drug) in tissue
homogenate, which was the sample we measured in the present study, microdialysis assay
measures only free soluble cocaine in extracellular fluid (Pan et al. 1991). Thus, it is
unsurprising to find that brain/blood ratio of cocaine obtained by microdialysis was ~2
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(Pan et al. 1991), compared to ~6.5 in our study. The difference between these assays may
explain the discrepancy in the observation.
However, the mechanism of how cocaine, a positively charged compound at
physiological pH (Li et al. 1999), rapidly distributes to brain remains unclear. Despite
previous thought that cocaine passively diffuses to brain in a deprotonated state, recently
Cisternino et al used in situ brain perfusion to investigate brain transport of cocaine. Their
findings suggested a co-existence of carrier-mediated transport and passive diffusion
(Chapy et al. 2015). In addition, based on the investigation of the atomic scale structure of
cocaine in aqueous solutions, Johnson et al. found that cocaine formed hydrogen bonds
with water, and the water-mediated conformation shielded the charges to form an external
hydrophobic environment, such that cocaine molecule becomes sufficiently lipophilic to
cross the blood brain barrier (Johnston et al. 2016). In addition, norcocaine, which is a
toxic metabolite of cocaine, has similar structure with cocaine (Evans et al. 1980). The
high brain/blood ratio of norcocaine may result from a similar mechanism. Overall, these
findings may explain high levels of cocaine and norcocaine in brain, and provide new
insights to understand the transport of cocaine and its role in addictive mechanisms.
Several cocaine pharmacokinetic models have been reported previously. Pan et al
developed a two-compartment PK model to investigate different PK profiles of cocaine
between naïve and cocaine-experienced rats. This two-compartment model was used to
describe cocaine concentrations in rat blood and extracellular fluid of nucleus accumbens
(Pan et al. 1991). The parameters estimated from their model were widely used in multiple
animal studies to predict cocaine concentration in rat brain. For example, in a study to
investigate the effect of acute stress on the acquisition of cocaine self-administration in rat,
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cocaine concentrations in rat brain were calculated based on those parameters (GarciaKeller et al. 2016). In another study, cocaine brain concentration predicted by that model
was used to predict dopamine uptake and dopamine release in rats following cocaine
administration (Siciliano et al. 2017). However, the observed data Pan et al. used to fit
their model was from microdialysis samples (Pan et al. 1991). As such, it was the free
cocaine concentration, instead of total cocaine (bound plus unbound) concentration, being
fitted and predicted by that model. Additionally, in a study reported by Sun and Lau, a PK
model that simultaneously fits the concentrations of cocaine and its metabolites norcocaine
and benzoylecgonine in rat serum has been proposed (Sun et al. 2001). They assumed that
norcocaine was formed mainly during the first-pass effect following p.o. administration,
while benzoylecgonine was formed both systemically in the central compartment and presystemically from the depot. This model well-characterized the serum concentration-time
profiles of cocaine, norcocaine, and benzoylecgonine in rats (Sun et al. 2001). However,
this model was only able to predict cocaine concentration in rat serum, without predicting
brain concentration. In addition, EME, one of the major metabolites of cocaine, was not
included in their model (Sun et al. 2001).
In conclusion, we have demonstrated the effects of CocH5-Fc(6M) in eliminating
cocaine and its active metabolites in rat blood and brain. We also developed a PK-PD
model to characterize the PK profiles of CocH5-Fc(6M) in rats, and to simultaneously
predict the levels of cocaine and its major metabolites in both rat blood and brain, in the
presence of highly efficient CocH5-Fc(6M). This model is expected to facilitate further
animal study design to evaluate the potential of CocH5-Fc(6M) for cocaine addiction
treatment.
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CHAPTER 5. GENERAL DISCUSSION AND CLINICAL PERSPECTIVES
BChE has been widely explored for its potential in anti-cocaine treatment (Gorelick
1997, Lynch et al. 1997). With the help of structure- and mechanism-based computational
modeling and simulation, BChE mutants have been designed with more than 1000-fold
enhanced catalytic efficiency against cocaine. These mutants have been characterized in
both in vitro and in vivo studies (Pan et al. 2005, Zheng et al. 2008, Xue et al. 2013, Zheng
et al. 2014). In Chapter 2, we have demonstrated the effectiveness of CocH1-HSA in
treating cocaine overdose in male and female rats. In the extreme scenario where rats
received a lethal dose (LD100) of cocaine, all the male and female rats were successfully
protected and rescued by CocH1-HSA within ~4 minutes. Additionally, in Chapter 3, we
aimed to evaluate the effects of CocH5-Fc(6M) in reversing alcohol-potentiated cocaine
toxicity. We compared the lethality of cocaine and its toxic metabolites in mice, and found
that cocaethylene and norcocaethylene, two alcohol-dependent metabolites of cocaine,
were more potent than cocaine in inducing death in mice, suggesting at least partial
contribution of these compounds to the enhanced toxicity when alcohol is co-administered
with cocaine. Further, we demonstrated the capacity of CocH5-Fc(6M) in reversing
toxicity induced by combinational use of alcohol and cocaine. Based on our observation in
preliminary experiments (data not shown), a single dose of 1 mg/kg CocH1-HSA was
unable to successfully rescue rats from 180 mg/kg cocaine (i.p.) + 1 g/kg alcohol (i.p.). In
comparison, as we demonstrated in Chapter 3, a single dose of 1 mg/kg CocH5-Fc(6M)
successfully protected and rescued rats against lethal combination of cocaine and alcohol,
suggesting improved efficiency of CocH5-Fc(6M) than CocH1-HSA in treating cocaine
overdose. Later, in Chapter 4, we switched our focus to cocaine addiction treatment. In this
95

study, we evaluated rat pharmacokinetic profiles of CocH5-Fc(6M), which was an Fc-fused
protein with extended elimination half-life. Linear pharmacokinetics of CocH5-Fc(6M)
was observed in rats. Based on this observation, a two-compartment model with linear
elimination from central compartment was developed, and it adequately described the PK
profile of CocH5-Fc(6M) in rats. In addition, a PK-PD model has been developed to
characterize the effects of CocH5-Fc(6M) on the distribution and metabolism of cocaine
and its metabolites ecgonine methyl ester, benzoylecgonine, and norcocaine in rat blood
and brain. The model predicted that CocH5-Fc(6M) accelerates the elimination of cocaine,
benzoylecgonine, and norcocaine, as well as the formation of ecgonine methyl ester. This
model is potentially applicable to facilitate further in vivo studies.
How to translate animal studies to human trials is always challenging. The rest of
this chapter will be a brief discussion of the perspectives on the clinical translation of
cocaine hydrolases. Several topics, including absorption, distribution, metabolism,
excretion (ADME) of therapeutic proteins, clinical perspectives and translational
considerations of CocHs, will be discussed.
5.1

ADME of therapeutic proteins
Due to the instability in the acidic environment of stomach, most therapeutic

proteins

are

administered

intravenously,

intramuscularly

and

subcutaneously.

Intramuscularly and subcutaneously injected therapeutic proteins are primarily absorbed
into circulation via convection through lymphatic vessels (Ezan 2013, Tibbitts et al. 2016).
Factors such as charge and size of biologics, may affect the absorption rate. Generally,
large and charged proteins are absorbed more slowly into the circulatory system (Ezan
2013, Tibbitts et al. 2016).
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Therapeutic protein distributes to different tissues either non-specifically or targetspecifically. Because of the tight endothelial barrier, biologics cross the vascular
endothelial cells at slow rates (Mahmood et al. 2005). Generally, biologics are poorly
distributed to tissues, especially to the brain. Various factors, such as charge, size, and
hydrophilicity of therapeutic protein, may have significant effects on this process. Highly
hydrophilic protein, and protein with large size are difficult to distribute to tissues (Wang
et al. 2008, Ezan 2013, Tibbitts et al. 2016).
Target-mediated disposition (TMDD) is an important characteristic of the
distribution and metabolism of protein drugs (Wang et al. 2008). Protein drugs bind to the
cell surface-expressed targets, and undergo endocytosis and subsequent lysosomal
degradation. Therefore, when protein drug concentration is much lower than the target
concentration, most of the drug is internalized and metabolized. However, at high
concentrations of protein drug, the targets will be saturated, leading to decreased
metabolism rate of protein drug and nonlinear PK profile (Tabrizi et al. 2006).
FcRn-mediated elimination also plays an important role in the metabolism of
protein (Wang et al. 2008). In the acidic environment of early endosome, the Fc domain of
IgG molecule binds tightly to FcRn, thus preventing delivery of IgG to lysosomes (Suzuki
et al. 2010). The IgG will be delivered back to the cell surface and released from FcRn at
the neutral pH outside of the cell. This mechanism explains the long biological half-life
(~3-4 weeks) of IgG (Suzuki et al. 2010). Serum albumin can also bind to FcRn and
undergo similar metabolism pathway (Ward et al. 2003, Ezan et al. 2014).
Small protein with a molecular size less than 60 kDa can be excreted by renal
filtration (Katsila et al. 2012, Ezan 2013). Larger protein can be degraded into small
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peptide fragments or amino acids by proteases in blood and lymphatic fluid, which can be
further excreted by kidney or recycled into protein synthesis (Xu et al. 2012).
5.2

Immunogenicity of therapeutic proteins
Immunogenicity is a potential limitation of therapeutic proteins. Due to their

foreign nature, most protein drugs induce immune response in human body. In addition,
aggregates, route of administration, dose, formulation-related factors, and characteristics
of patients, may also contribute to immunogenicity (Chirino et al. 2004, Kessler et al.
2006). Therapeutic proteins induce immune response by activating antibody-secreting B
cells. Secreted anti-drug antibodies (ADAs) may neutralize protein drugs, and thus
accelerate the elimination of protein drugs, leading to reduced efficacy (Wang et al. 2008,
Baker et al. 2010, Sethu et al. 2012). Therefore, reducing immunogenicity is one of the
major tasks in the development of therapeutic proteins. Several approaches, such as
optimization of manufacturing processes, pegylation of proteins to shield epitope,
designing fully humanized protein drugs, have been developed to reduce immunogenicity
of protein drugs (Jullien et al. 2015).
Since

CocHs

were

designed

based

on

human

endogenous

enzyme

butyrylcholinesterase, we expect low immunogenicity induced by CocHs in human, In fact,
in the clinical trials conducted by Teva Pharmaceutical Industries, although anti-CocH1HSA antibodies were observed in three out of 24 patients receiving multiple ascending
dose, no immunogenicity for CocH1-HSA (TV-1380) was seen in patients in the single
ascending dose group (Cohen‐Barak et al. 2015). The ADA induced by TV-1380 was
reduced in the follow-up visit (Gilgun-Sherki et al. 2016).
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5.3

Clinical perspectives of therapeutic proteins
Biologics often require complex manufacturing and storage processes (Thomas

Morrow 2004), and thus are generally more expensive compared to small-molecule drugs,
and can cost patients thousands of dollars monthly (Thomas Morrow 2004). However,
biologics appeared to be worth their cost (Raval et al. 2011). For example, small-molecule
drugs 5-aminosalicylates (5-ASA), corticosteroids and immunosuppressants are
conventional therapies for patients suffering inflammatory bowel disease (IBD). During
the prolonged treatment, no significant improvement of health-related quality of life
(HRQoL) was observed in patients using these drugs, partly because of the associated side
effects. In comparison, anti-tumor necrosis factor (anti-TNF) protein drugs such as
infliximab, adalimumab, certolizumab, and natalizumab demonstrated significant
improvement of HRQoL in IBD patients, due to rapid induction and long-term remission
(Vogelaar et al. 2009). Therefore, although biologics are more expensive than the
conventional small-molecule drugs, biologics are indeed expected to be cost-effective,
considering the cost associated with inpatient care, medications in the prolonged treatment
(Vogelaar et al. 2009).
5.4

Safety of cocaine hydrolases
BChE, as a cousin of acetylcholinesterase (AChE), acts as a backup enzyme to

regulate acetylcholine (ACh) levels (Li et al. 2000). Therefore, one major concern about
the safety of CocH is that highly efficient CocH might also have an enhanced activity
against acetylcholine, thus resulting in undesired effects. Taking this into account, an ideal
BChE mutant should have considerably improved catalytic activity against cocaine, while
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lacking significant effect on ACh. In fact, cocaine hydrolases were designed by accounting
for the mutation-caused changes of catalytic activities of BChE against both (-)-cocaine
and ACh. In our previous report, while having significantly improved catalytic efficiency
against (-)-cocaine, CocH1 was ~2.8-fold less efficient than wild-type BChE in
hydrolyzing ACh (Xue et al. 2011). Moreover, Brimijoin et al. found no adverse
physiological or metabolic effects in mice receiving gene-delivered CocH, despite ~1500fold higher levels of CocH above baseline (Murthy et al. 2014). In the clinical studies,
following intramuscular injections, 0.5-300 mg of HSA-fused CocH1 (i.e. TV-1380) was
well tolerated in patients. No side effect was reported directly related to TV-1380. No
evidence suggests that the TV-1380 changed the activities of endogenous BChE and AChE
in patients (Cohen-Barak et al. 2015). Overall, these results clearly demonstrate that
cocaine hydrolase would be safe in human.
Another common concern is the toxicity and rewarding effects of cocaine
metabolites generated by cocaine hydrolase. CocHs accelerate the metabolism of cocaine
to generate ecgonine methyl ester (EME) and benzoic acid (BA). In our animal studies, we
did not observe EME-induced side effects in rats. Likewise, in a study reported by
Brimijoin et al., place preference was observed in mice receiving 20 mg/kg cocaine, while
equivalent combined dose of EME + BA failed to induce such effects. Further, in
comparison to the control group, 80 mg/kg cocaine failed to affect blood pressure in mice
receiving gene-delivered CocHs (Murthy et al. 2015). Together, these observations
confirm the eligibility of CocH for anti-cocaine therapy.
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5.5

Translational considerations for cocaine hydrolases

5.5.1

PK considerations

As we discussed above, FcRn/Fc interaction prevents IgG from degradation, which
explains long elimination half-life of IgG (Suzuki et al. 2010). Inspired by this mechanism,
increasing effort has been focused on engineering the Fc domain to extend the half-lives of
therapeutic proteins. By increasing the binding affinity between FcRn and Fc at pH 6.0,
the Fc-containing proteins are expected to have a long in vivo half-life (Hinton et al. 2006).
For example, N434A, a human IgG variant that has ~4-fold increased binding affinity to
nonhuman primate FcRn at pH 6.0, yielded ~2-fold decrease in clearance in cynomolgus
monkey (Yeung et al. 2009). We recently reported a triple-mutated Fc with enhanced
binding affinity to FcRn at pH 6.0. By fusing this mutated Fc to cocaine hydrolase, we
observed ~107 h elimination half-life of Fc(3M)-fused CocH in rat, compared to ~86 h of
wild-type Fc-fused CocH (Chen et al. 2016). Additionally, our recently designed sixmutated Fc has further enhanced binding affinity to both human and rat FcRn (data not
shown). We expect that Fc(6M)-fused CocHs yield a further extended in vivo half-life.
PK parameters were scaled across species by frequently applying the principles of
allometry, assuming that physiological parameters in species vary as a function of body
weight (Deng et al. 2011). However, as FcRn plays a critical role in the PK profile of
CocH-Fc, conventional allometric scaling may not directly applied to project human PK
profiles of CocH-Fc without considering FcRn abundance and FcRn/Fc binding affinity
across different species. Regarding this, a physiologically-based pharmacokinetic (PBPK)
model incorporating FcRn/Fc binding would be helpful to translate the disposition of
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CocH-Fc in human (Garg et al. 2007, Shah et al. 2012). Overall, considering the increased
binding affinity of Fc(6M) than wild-type Fc with human FcRn, we expect a satisfying
half-life of CocH-Fc(6M) in human.
5.5.2

PD considerations

Chest pain is the most common symptom of cocaine overdose in patients visiting
the emergency department (Fortney et al. 2011). In a study that examined 112 patients
(including two died) presenting to emergency department, the mean blood cocaine
concentration is patients was 0.26 mg/L (~0.86 M) (Blaho et al. 2000). In this dissertation,
a single dose of 5 mg/kg CocH1-HSA or 1 mg/kg CocH5-Fc(6M) successfully rescued rats
from an extreme serious condition, when blood cocaine concentration was much higher
than the concentration in ED-visiting patients. All the rats recovered quickly after enzyme
administration. Therefore, we expect CocHs to be sufficiently effective in treating cocaine
acute toxicity in human.
On the other hand, treating chronic cocaine addiction requires a long-acting
intervention (Woods et al. 2016). Therefore, Fc-fused CocHs were designed with the
purpose to elongate biological half-life. The long-acting form of CocHs would require
lower doses and less dosing frequency for administration, thus reducing the cost of therapy
(Gilgun-Sherki et al. 2016). In addition, CocHs efficiently accelerate the hydrolysis of
cocaine, which would protect patients from experiencing cocaine-induced effect in the
long-term treatment. We anticipate that over time, without further damage to the CNS, the
brain communication system would be back to normal (Murthy et al. 2015).
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5.6

Summary
The present dissertation evaluated the pharmacokinetic and pharmacodynamic

properties of cocaine hydrolases for its use in anti-cocaine treatment. Both CocH1-HSA
and CocH5-Fc(6M) displayed linear pharmacokinetic profiles in rats. Both enzymes
effectively hydrolyze cocaine and its toxic metabolites in rats. In addition, a mathematical
model was developed in this dissertation. The model adequately described the kinetic
profiles of cocaine and its metabolites in the presence of CocH5-Fc(6M), and is expected
to facilitate further experiment design. The promising pre-clinical results discussed in this
dissertation warrant further clinical development of cocaine hydrolases.
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